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1 INTRODUCTION 
 
Self poisoning is the most common form of deliberate self harm and is an important 
cause of death among young people.(1) Pesticides are the most common cause for 
deliberate self harm in developing countries due to easy availability and low cost.(2) 
There are estimated 500 000 deaths from deliberate self harm each year, out of which 
60% are due to insecticide consumption.(2) Organophosphates(OP) are extensively used 
in rural Asia as agriculture remains the mainstay of livelihood and thus deliberate or 
accidental ingestion of these compounds are common.(3) The high case fatality in rural 
areas could be because of lack of hospital services or hospitals being under- staffed, poor 
transport facility and non availability of specialized care like mechanical ventilators or 
definitive antidote.(4)  Medical management is difficult and involves immediate 
resuscitation, gastric decontamination, antidote and supportive care.(5) Gastric lavage is a 
common procedure used to decontaminate the stomach, though there are not many 
randomized controlled trials favoring its benefit. (6,7) Most of the guidelines for 
management of insecticide poisoning advice gastric lavage only for patients who arrive 
within 1 hour after ingestion of the poison to the hospital.(8) There are various 
complications associated with the procedure which have been described in literature like 
aspiration pneumonia, gastric perforation, arrhythmias and even cardiac arrest in some 
patients.(9) Though evidence is sparse, it is still a commonly done procedure; it is the 
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standard of care in India and is a legal requirement. Despite lack of evidence of its 
effectiveness, it is a widely used. Doctors in India performed gastric lavage for the 
majority of their patients with ingestion of poisons. (10) 
In this setting of lack of evidence for the procedure, this study is planned to assess the 
“proof of concept” for potential benefit of gastric lavage in acute organophosphate 
poisoning. The proposed research is a study to measure the amount of organophosphate 
compound removed from the stomach by gastric lavage, based on the idea that if gastric 
lavage is effective then the amount of OP will be undetectable at the end of the procedure 
and a significant amount of OP would have been removed during the lavage process. 
Such a study has not been conducted based on our review of the published literature. 
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2 AIM 
To assess the effectiveness of gastric lavage in removing measurable organophosphate from the 
stomach in patients with acute organophosphate poisoning  presenting to a tertiary care centre in 
South India 
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3 OBJECTIVES 
1. To measure the amount of organophosphate removed from the stomach by gastric lavage. 
2. To know the difference in the concentration of OP in the stomach before and after gastric 
lavage. 
3. To find out the number of cycles of gastric lavage required to remove the organophosphate 
from the stomach. 
4. To assess the determinants of the concentration of organophosphate in the stomach at 
presentation - amount of OP compound consumed, lag time between consumption to gastric 
lavage and prior decontamination procedures. 
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4 REVIEW OF LITERATURE 
4.1 EPIDEMIOLOGY OF POISONING 
Deliberate self harm due to poisoning is a global public health problem.(11) According to 
WHO, over 800,000 people die due to suicide every year with an estimated 193,460 
people dying worldwide from unintentional poisoning . (12) Suicide accounted for 1.4% 
of all deaths worldwide and was the second leading cause of death among young people 
globally in 2012.(13) 75% of global suicide occurred in low- and middle-income. The 
substances used are usually easily available in the home or can be bought over the 
counter. The toxicity of the available poisons and lack of medical services ensure that 
mortality from self‐poisoning is greater in the developing countries than in the 
industrialized world. (14) 
In India, 187 000 suicide deaths were reported in 2012 which was close to the WHO’s 
estimates.(15) Poisoning, mainly from pesticides (organophosphates) which are used in 
agriculture, was the leading cause of suicide in both men and women, which accounted to 
about 92 000 deaths nationally. A higher number of deaths due to suicide during the last 
few years were reported from states of Tamil Nadu, West Bengal, Andhra Pradesh, 
Maharashtra and Karnataka which together  accounted for 56.2% of the total suicide as 
per the National Crime Records Bureau (NCRB).(16,17) 
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Figure 1: Pesticides as a cause of fatal self-harm in Asia (19) 
According to Government of India statistics, the report on medical certification of cause 
of death 2011, “Injury, Poisoning & Certain Other Consequences of External Causes” 
accounted for 7.8% of all medically certified deaths and were the major cause of 
mortality in the age group of 15-24 and 25-34 years accounting for 27.5%  and 23.5% 
deaths respectively.(18) Based on the availability of poisons and the reporting system, the 
data on poisoning has been fluctuating. Lack of proper reporting system may be a 
limitation and thus the above numbers may not be a true reflection of the actual problem. 
The Million death Study in India reported that the cumulative risk of dying of suicide 
before 80 years was 1.2% with Tamil Nadu being in the highest risk (2.2%).(19) 
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4.2 EPIDEMIOLOGY OF PESTICIDE POISONING IN THE WORLD 
Pesticides when used properly offer a wide variety of benefits to society. They are useful 
in increasing crop production and combatting  insect infestations.(20) However, 
pesticides also have the potential for causing harm as in accidental exposures and 
deliberate self-harm. Most cases of deliberate self harm seem to be impulsive acts due to 
inability to cope with stressful events, and the easy availability of lethal pesticide 
compounds over the counter. WHO estimates that three million cases of pesticide 
poisoning occur every year, causing an excess of 250000 deaths worldwide. Of these 
cases, one-third are accidental and two-thirds are due to deliberate self-harm.(21) The 
majority of the cases were reported from India, China, Vietnam and Sri Lanka. South-east 
Asia has the highest number of suicides due to pesticides, 20.7% as compared to 4.7% 
and 3.9%  respectively in Europe and America.(12) Lately, a large number of intentional 
pesticide poisoning has been reported from other low and middle income countries. 
Organophosphate pesticides are the most common cause for death from intentional 
pesticide poisoning. (22) 
 
4.3 PESTICIDE POISONING – THE INDIAN SCENARIO 
Agriculture is a major component of the Indian economy: it contributes 22% of the 
nation’s GDP and is the livelihood of nearly 70% the country’s workforce.(8) The million 
death study estimated 187,000 deaths every year due to organophosphate poisoning 
which accounted to almost half the suicides in the country. A study done in Andhra 
 
 
24 
 
Pradesh included  8040 patients with pesticide poisoning with an overall case fatality 
ratio was 22.6%.(23) Monocrotophos and endosulfan, were responsible for most of the 
deaths.(23)  Another study done Maharashtra showed organophosphorus to be the cause 
for mortality in 43% of the deaths due to poisoning. (24) The reason for pesticide 
poisoning to be the most popular means for suicide is the easy over the counter 
availability and the lethality of the compounds. Thus, suicide prevention strategies should 
include a ban on lethal compounds, restrictions on access to pesticides and safety 
regulations regarding sale of these compounds.(3,25,26) 
4.4 IMPLICATIONS OF RESTRICTION ON TOXIC PESTICIDES 
There has been evidence suggestive that any difficulty in procurement of a commonly 
used  means for suicide may influence the overall suicide rates.(27)  One of the  strongest 
evidence is from the 1960s study on detoxification of Britain’s  domestic gas supply.(28) 
A similar trend in decline in suicide rates was seen in Australia following restriction in 
the availability of barbiturates.(29) 
Pesticides are easily available in  most rural households as well as over the counter in 
developing countries, which are used by impulsive young individuals under stressful 
conditions.(30,31) Thus, an effective strategy to reduce these deaths would be to regulate 
the availability and procurement of these compounds. The WHO and FAO have 
recommended a ban on  Ia and Ib pesticides (extremely and highly hazardous) and to use 
those that are least toxic to man.(32,33) Based on these, various pesticides have been 
banned in India like Endosulphan and others restricted such Monocrotophos, which is not 
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allowed for use in vegetable crops. (34) Despite restriction of monocrotophos, it is one of 
the most common causes of deliberate self-harm. Most lethal organophosphates, like 
parathion, monocrotophos, methylparathion and methamidophos were banned in Sri 
Lanka by 1984 and by 1995 all class I WHO compounds were banned. During this 
period, there was a transitional rise in the suicide mortality rates in Sri Lanka due to the 
prevalent use of endosulfan. Subsequently in 1998 Endosulphan was also banned 
following which as a progressive fall in deaths due to suicide was noticed. (27) 
Reducing access to lethal pesticides and allowing the marketing of less toxic compounds 
for agricultural may be instrumental in bringing down the burden of the problem. 
Increasing awareness among farmers regarding use and toxicity of pesticides along with 
better management of acute poisoning may be effective in lowering the deaths.(2) 
Eddleston et al put forth the development of a minimum list of pesticides which were less 
dangerous.(35) 
However,  India lacks a  regulatory system regarding the usage of pesticides.(34) The 
Insecticides Act of 1968 is a key piece of legislation that is supposed to govern the use, 
manufacture, distribution, sale and transport of insecticides with a view to lowering risks 
to human health. (36) The slackness in the implementation of these legislative policies 
and procedures may have an impact on the mortality rates and the profile of poisonings. 
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4.5 POISONING EXPERIENCE IN CMC, VELLORE 
A survey carried out on in Christian medical college, Vellore during the period between 
July 2009- June 2011 showed that 70% of all poisonings and 12% of all medical 
intensive care unit admissions were due to organophosphate poisonings. 621 pesticide 
poisonings were reported during the period, with organophosphates (54.4%) being the 
most common cause and mortality. 70% of all the organophosphates belonged to the 
highly toxic class I category with a case fatality rate of 8.4%. The total number of 
organophosphates poisonings in CMC Vellore from January 2014-april 2014 was 53. Out 
of which 37/53 received gastric lavage before reaching the hospital and 30/53 received 
gastric lavage in CMC. A study done in our institution included 78 patients, out of which 
69(88.5%) identified the compound. Another study done on organophosphorus poisoning 
during the period 2012-2014 included 78 patients, out of which in 88.5% the compound 
was identified and 56% had received gastric lavage prior to reaching CMC. 
 
4.6 ORGANOPHOSPHORUS COMPOUNDS 
Organophosphorus(OP) compounds are derivatives of phosphorus and have been widely 
used as pesticides and nerve agents. Between  1934–1944, Gerhard Schrader, a German 
chemist  synthesized around 2000 OP compounds, some like sarin ,tabun and soman as 
agents for chemical warfare.(37) During the Iran-Iraq war (1980–1988), use of nerve 
agents was reported. They were used in chemical warfare and terrorist attacks. Today 
these compounds are used in agriculture and public health as insecticides, ascaricides, 
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fungicides and nematocides. Organophosphorus compounds are easily accessible and are 
often used to commit suicides.  Accidental poisoning may also occur especially when 
they are kept within the reach of children. Farmers could get exposed while spraying 
crops if they are not well protected with masks, gloves and other protective clothing. 
Studies have shown that these are the most common cause of suicide in India in view of 
the large farming community.(24) 
 
4.7 CHEMICAL COMPOSITION OF ORGANOPHOSPHORUS 
COMPOUND 
The first organophosphorus (OP) compound tetraethyl pyrophosphate (TEPP) was 
synthesized in France by de Clermont. Later, von Hofmann synthesized methyl-
phosphoryl dichloride.(38) OP structure consists of a tetra-substituted phosphorous centre 
with a double bonded oxygen or sulphur atom and a leaving group with two other 
substituents depending on the compound subclass.(39) 
 
Figure 2: Chemical structure of organophosphorus molecule(39) 
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4.8 CLASSIFICATION OF ORGANOPHOSPHORUS COMPOUNDS 
The various ways of classification of organophosphorus compounds are as follows:(40) 
4.8.1 1. Depending on whether they are pro-poison or active poison 
a) Thion (pro-poison) - sulphur atom attached to phosphate atom (P=S) and needs 
conversion by CYP450 in gut wall or liver to active oxon (P=O) for clinical effects - 
Parathion, Chlorpyrifos, Dimethoate 
b) Active oxon form – They don’t require activation and are hence faster -  Profenofos, 
Dichlorvos 
4.8.2 2. WHO classification based on rat LD50 
 
Table 1: WHO classification of Pesticides(2009 update) (32) 
WHO CLASS                                                                               LD50 for rat 
                                                                                                 (mg/kg body weight) 
                                                                                            Oral                              Dermal 
Class Ia                        extremely hazardous                     <5                                     <50 
Class Ib                        highly hazardous                         5-50                             50-  200 
Class II                        moderately hazardous            50-2000                           200-2000 
Class III                       slightly hazardous                     >2000                                >2000 
U                              unlikely to present acute hazard                          5000 or higher 
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The classification is done based on the lethal dose (LD50) measures on rats both for oral 
as well as dermal exposure. Lethal dose (LD50) is amount of toxin (mg per kg of body 
weight) required for killing 50% of the population. 
Few commonly used pesticides are given below: 
 Class Ia – Parathion, Methyl-parathion 
 Class Ib – Dichlorvos, Dicrotofos, Monocrotofos, Triazophos 
 Class II  – Chlorpyrifos, Diazinon, Fenthion, Quinalphos 
 Class III – Methylchlorpyrifos, Malathion 
 
4.8.3 3. Chemical structure :   
 
The alkyl group in organophosphorus compounds can be either a methyl/ethyl/salkyl 
group. The prognosis is poorer on consumption of dimethyl compounds as  compared to 
ethyl compounds.(41,42) This could be because of the fact that half life of dimethyl 
compounds are shorter  (half life of diethyl - 30hours ,dimethyl - 3 hours,) and their 
capacity to regenerate oximes is also low.(43) 
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Table 2: Classification of OP compounds based on chemical composition (41) 
Dimethyl                              Diethyl S-alkyl 
Monocrotophos                    Phorate Profenophos 
Methylparathion                  Triazophos  
Dichlorvas                           Quinalphos  
Dimethoate                          Chlorpyriphos  
Phenthoate                           Ethion  
Malathion  
Acephate  
 
4.8.4 4. Lipid solubility – 
Compounds with high lipid solubility have a longer duration of action with a delayed 
onset, they can cause sudden increase in compounds causing a severe cholinergic crises. 
The common lipid soluble organophosphorus compounds are –Chlorpyrifos, Parathion, 
Fenthion, Dichlorfenthion. 
4.9 TOXICITY AND CLINICAL MANIFESTIONS 
Organophosphate pesticides inhibit carboxyl ester hydrolases, especially 
aetylcholinesterase (AChE) which is an enzyme that degrades the neurotransmitter 
acetylcholine (ACh) into choline and acetic acid. Hence, there is accumulation of 
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acetylcholine at the synapses and overstimulation of muscarinic and nicotinic receptors of 
the central, autonomic nervous system and neuromuscular junction.(44) 
AChE, an esterase enzyme has two binding sites, which are the anionic and esteratic 
sites. The toxicity of OP compounds are mainly due to the inhibition, i.e. phosphylation, 
of the active site serine in AChE.(45) Thus, there is inactivation of the enzyme that 
prevent esteratic cleavage of AChE and leads to accumulation of acetylcholine at the 
nerve endings.(46) The clinical symptoms in OP poisoning are due to activation of the 
cholinergic system which can involve the muscarinic or nicotinic receptors. The 
muscarinic receptors receive  innervation from post-ganglionic parasympathetic fibres 
which control glandular activity, the smooth muscles of gastrointestinal and respiratory  
systems, and the efferents to the heart while the nicotinic sites cause contraction of 
skeletal muscle through autonomic ganglia.(47) Thus, accumulation of acetylcholine 
causes generalised, prolonged central and peripheral post-synaptic stimulation. 
The cholinergic manifestations of organophosphorus poisoning are based on the 
receptors, they can produce muscarinic ,nicotinic or central symptoms.(48) 
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Table 3: Clinical manifestations of OP poisoning (48) 
MUSCARINIC NICOTINIC CENTRAL 
Respiratory 
 
 Anxiety 
Bronchorrhea/bronchospasm 
 
 Restlessness 
Rhinorrhea  Convulsion 
Cardiovascular Cardiovascular Insomnia 
Bradycardia Tachycardia Dysatrthria 
Hypotension Hypertension Tremors 
Gastrointestinal Musculoskeletal Coma 
Increased salivation Weakness Absent reflex 
Nausea/vomiting Fasciculation Cardiovascular collapse 
Abdominal pain Cramps Respiratory suppression 
Diarrhea/ fecal incontinence Paralysis  
Genito-urinary   
Urinary incontinence   
Ocular   
Lacrimation   
Blurred vision/miosis   
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4.10 SYNDROMES OF ORGANOPHOSPHORUS POISONING 
4.10.1 Acute cholinergic crises:  
During this phase, mainly muscarinic symptoms are seen which can be graded 
based on the Namba scale.(49) 
 
Table 4: Namba severity scale (49) 
Namba scale Clinical presentation 
Namba 1 or Latent  No clinical manifestations 
 Assessment of severity is by measurement 
of serum cholinesterase level which will 
be inhibited by 10-50% 
Namba II or Mild  The patient is able to walk but complains 
of dizziness, headache, nausea and 
vomiting, numbness of extremities, 
excessive sweating and salivation, 
abdominal cramps, tightness in chest or 
diarrhoea 
 Serum cholinesterase level is 20-50% of 
normal 
Namba III or Moderate  The patient is unable to walk and there is 
difficulty talking, generalised weakness, 
muscular fasciculation, and miosis. 
 Cholinesterase level is 10-20% of normal 
Namba IV or Severe  Unconsciousness, loss of pupil reflex to 
light and marked miosis, flaccid paralysis, 
muscular fasciculation, secretions from 
the mouth, moist rales in the lungs and 
nose, respiratory difficulty and cyanosis. 
 Serum Cholinesterase levels < 10% of 
normal 
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4.10.2 Intermediate syndrome(IMS):  
IMS is one of the major causes for mortality and morbidity in organophosphate 
poisoning. The term was first coined in 1987 by Senanayake et.al. (50) It typically occur 
within 24 to 96 hours and causes weakness of muscles of  respiration, proximal limb, 
muscles innervated by motor cranial nerves and neck flexors. Usually with mechanical 
ventilation, complete recovery happens in 5-18 days.(51) Various mechanisms have been 
proposed for the development of intermediate syndrome like delayed release of 
organophosphorus compounds from adipose tissue causing a delayed paralysis,(52) 
persistent nicotinic effects due to lack of early initiation of oxime therapy and even 
neuromuscular junction dysfunction has been postulated.(50) The other theories put forth 
were oxidative stress-induced myopathy, muscle necrosis and desensitisation of 
acetylcholine receptors. A study done in India showed an incidence of IMS of  29.4% 
with mortality of 22.3%.(53) The compounds with the highest incidence of IMS were 
methylparathion and monocrotophos .(53) Another entity called delayed 
organophosphate encephalopathy (DOPE) can also develop during this period and it 
manifests with altered sensorium and miosed pupils.(54) 
 
4.10.3 Delayed manifestations : 
 These patients can have delayed manifestations like behavioural changes, 
neuropyshiatric changes and peripheral neuropathy. Delayed organophosphorus 
encephalopathy has been described in organophosphorus poisoning. A study done in 
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Christian medical college, Vellore described 35 patients with organophosphorus 
poisoning who developed delayed encephalopathy.(55) 
4.11 MANAGEMENT OF ORGANOPHOSPHORUS POISONING 
4.11.1 PRINCIPLES OF THERAPY: 
Early management of organophosphate poisoning can be life saving. Immediate 
assessment and stabilizing the airway, breathing, and circulation is one of the keystones 
in management. The  amount consumed, lag time since ingestion and first hospital 
contact, prior decontamination procedures and clinical features are essential to guide 
further management.(56)  Skin decontamination is necessary with removal of exposed 
clothing  and washing the patient with soap and water.(57) Management involves 
resuscitation, antidote, gastric decontamination, and supportive care. The commonly done 
decontamination procedures are gastric lavage, ipecac and activated charcoal.(7) The 
effectiveness of gastric lavage has been debated for the past many years, yet it is a 
commonly done procedure; it is the standard of care in India and is a legal 
requirement.(8) 
4.11.2 GASTRIC DECONTAMINATION PROCEDURES 
Gastric decontamination procedures remove the ingested toxin from the gastrointestinal 
tract(GI),thus by decreasing the amount of toxin in the GI tract they also decrease its 
absorption. This may decrease the life threatening complications of the toxin.(7)  
Historically, the various approaches adopted are gastric lavage, activated charcoal and 
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whole bowel irrigation or cathartics.(58) But with evolution of clinical practice, the 
benefits of decontamination procedures have been questioned. 
4.11.2.1 IPECAC 
Ipecac syrup was widely used in the early 1980’s to induce vomiting after acute  
poisoning both in the hospital and at home.(59) It was suggested that it was better than 
parenterally dosed apomorphine.(60) Ipecac is made of alkaloids from the plants cephalis 
ipecacuanha and  cephalis acuminate. Emetine and cepheline, active components of 
these plants cause gastric irritation and stimulate the chemotrigger zone of the brain thus, 
inducing emesis. This procedure is obsolete now due to the various serious complications 
like persistent vomiting, aspiration pneumonia, Mallory Weis tear of oesophagus and 
barotraumas to mediastinum. 
A study done on 10 healthy subjects with ingestion of 3 gm of acetaminophen, followed 
by either ipecac, 50g Activated charcoal (AC) or no intervention at 1 hour of intervention 
showed that there was reduction of serum acetaminophen levels in the intervention group 
as  compared to controls, However there was no difference between ipecac or AC.(61)  4 
randomized trials, comparing forced emesis with ipecac followed by activated charcoal 
versus activated charcoal alone showed no added benefits of using both the procedures 
together. (62–65) 3 out of the 4 trials showed high complication rates with forced emesis, 
particularly aspiration pneumonia.(64) 
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In light of evidence not favouring the use of ipecac, the position statement of AACT and 
EAPCCT concluded that the use of ipecac in emergency department should be stopped. 
(66) There has been a drastic decrease in the number of patients with acute poisoning 
receiving ipecac, from 14.99% (132,947) in 1985 to 0.02% (658) in 2009.(67) 
4.11.2.2 GASTRIC LAVAGE 
The American Academy of Clinical Toxicology (AACT) recommends that gastric lavage 
be done using a large bore orogastric tube, such as 36-40 French, through which small 
aliquots are instilled into the stomach and reaspirated.(68) In 1966, Matthew et al. studied 
the efficacy of gastric lavage on 259 patients with acute poisoning and  concluded that if  
done within 4 hours, then could be beneficial as demonstrated by the significant removal 
of barbiturates in the lavage fluid.(69) A study done on volunteers with ingestion of 
acetaminophen who underwent gastric lavage showed significant decrease in the levels of 
acetaminophen if done within 1 hour.(68) However, two other small volunteer trials with  
aspirin/non-steroidal anti-inflammatory drug ingestion showed no advantage of gastric 
lavage over activated charcoal alone.(70) Nasogastric tube has been used for gastric 
lavage with equal effectiveness and low complication rate. (78) As per the AACT and the  
European Association of Poisons Centres  2013 position paper on gastric lavage, poison 
centers hardly recommend gastric lavage and its use has also been gradually declining. At 
present, the evidence supporting the beneficial effect of gastric lavage in poisoned 
patients is weak. The evidence for certain situations where gastric lavage may be 
beneficial like lethal ingestion, recent exposure and substance not bound to activated 
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charcoal are theoretical or are based on case reports. Thus, it concludes that gastric lavage 
should not be a routine procedure and recent evidence since 2004 suggests that it should 
be performed only where the expertise exists.(71) 
Gastric lavage is definitely contraindicated in corrosive and hydrocarbon ingestion. (72) 
Guidelines from the West don’t recommend gastric lavage and advice its use only if 
patient presents within 1 hour or ingestion of a large quantity of toxin. (73) Gastric lavage 
is still a commonly done procedure and it is the standard of care in India .(74) Despite 
lack of evidence of its effectiveness, it is a widely used (75). A study done by Sassan et al 
showed the doctors in India performed gastric lavage for the majority of their poisoned 
patients.(74) 
 
Figure 3: Prevalance of use of gastric lavage (74) 
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Currently, there is no evidence that gastric lavage  should be used routinely in the 
management of poisonings.(65,76) There are various complications associated with 
gastric lavage. Several studies have been published regarding the risks. Aspiration is one 
of the major concerns of gastric lavage. Eddleston et al. observed 14 patients in Sri Lanka 
who underwent the procedure and found that half of them developed aspiration and 3 
died soon after the procedure .(77) Wang et al. studied the respiratory complications 
associated with gastric lavage. In this study patients were given gastric lavage along with 
activated charcoal and they found that  21/33 (64%) patients who underwent lavage in the 
study hospital developed respiratory failure and  3/21(14%) developed pneumonia (78). 
The activated charcoal was pointed out to be the major predictor for respiratory failure. 
Another  study done in India on 98 patients with acute insecticide poisoning showed 
aspiration pneumonia to be a complication in 2.2-13.2% of the patients.(79) Electrolyte 
abnormalities have also been described, with  significant decrease in serum calcium, 
ionized calcium, and magnesium  (80). The other complications that have been described 
are oesophageal or gastric perforation, arrhythmias and in some cases even cardiac arrest 
(81). It is  thought that gastric lavage causes propulsion of poison beyond the pyloric 
sphincter into the small bowel, however there is no significant data to suggest the 
same.(82) 
In view of these complications and the lack of evidence of its effectiveness, the use of 
gastric lavage is questionable.(83) A systematic review on gastric lavage in OP poisoning  
was done which included 23 RCTs, of which there were no studies that had a control 
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group not receiving lavage. All these RCT’s were small and had poor methodology. The 
technique of gastric lavage also varied markedly between studies. Thus, there is no high 
quality evidence regarding the use of gastric lavage in OP poisoning and it is a much 
needed area for research. A study combining clinical with biochemical outcomes is likely 
to be more definitive and more widely accepted, an RCT of this kind has been proposed 
(84). Having said all this, in developing countries mortality is high and gastric lavage is a 
simple and easy technique.(68) So, prevention of absorption of even a small amount may 
make a considerable difference.(85) Furthermore, developing countries have poor 
resources with difficulty in getting antidotes and specialized care. Thus, any treatment 
option which is easy and cheap to carry out cannot be neglected. 
 
4.11.2.3 ACTIVATED CHARCOAL 
Activated charcoal is the only form of gastrointestinal decontamination that is still 
commonly used.(86) It adsorbs the ingested organophosphate compounds and thus 
decreases the amount of poison in the stomach.(87) It is believed that charcoal may work 
long after ingestion by interrupting the enterovascular and entero hepatic cycling of 
poison. Some studies suggest that multiple doses of activated charcoal may aid in 
elimination of the poison.(88) A study done in Sri lanka in 2003 by de Silva et al. looked 
at the effect of multi dose activated charcoal versus single dose activated charcoal in 
yellow oleander poisoning. The case fatality was   5 (2·5%) of 201 patients in multi- dose 
activated charcoal and  16 (8%) of 200 in single-dose activated charcoal, which was not 
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clinically significant. (89) Activated charcoal is practiced as a standard of care , however, 
randomized controlled trials of multiple dose activated charcoal in all poisoning in 
Srilanka showed no clinical benefit of the treatment.(90) This discordance could be due 
to various factors like faster absorption of the compound into the blood, late presentation 
to the hospital or a large dose ingested.(91) In the present scenario, there is no evidence 
that gastric lavage and activated charcoal have a definite role in poisoning management. 
However it is possible that these treatment may be beneficial in patients who present 
early. 
 
4.11.3 ATROPINE 
The mainstay of specific therapy for OP poisoning remains anticholinergic agents with 
clinical data showing the efficacy of atropine in preventing respiratory failure.(6) 
Atropine blocks the effects of organophosphorus compounds on muscarinic sites. 
Atropine is given in incremental doubling doses until the chest is clear and to maintain a 
heart rate of more than 80 beats per minute followed by an infusion.(92) One of the main 
side effects of giving high doses of atropine is anticholinergic delirium. (93) 
 
4.11.4 OXIMES 
Oximes help by reactivating the acetylcholinesterase  enzyme inhibited by 
organophosphorus compounds.(94) Their benefit has been shown in animal models, in-
vitro and in poisonings. Pralidoxime was one of the first oximes to be introduced in 
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1950’s.(95) Since then, other oximes like obidoxime and trimedoxime have also been 
marketed, but pralidoxime  continues to be the most widely used oxime.  The use of 
pralidoxime is controversial despite its benefits.  Although WHO recommends the use of 
oximes in organophosphorus poisoning(96), A Cochrane review comprising of 2 
randomised trials has not shown any significant benefit or complication.(97) A 
randomized trial done in Sri Lanka studied 235 patients who were randomized to receive 
either pralidoxime or placebo. It showed no significant difference in mortality between 
both the groups.(98) Studies done in Christian medical College,Vellore on the role of 
pralidoxime in acute poisoning have reported that it may cause harm.(99) However, 
Eddleston suggested that oximes may be beneficial in a sub group of patients which may 
have been masked by the majority showing ineffectiveness of the therapy. Thus, oxime 
therapy may be beneficial in certain groups of patients with organophosphorus 
poisoning.(98,100) 
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5 JUSTIFICATION 
The aim of the study was to assess the effectiveness of gastric lavage in removing 
measurable organophosphate from the stomach in patients with acute organophosphate 
poisoning  presenting to a tertiary care centre in South India 
Organophosphorus compounds are commonly available pesticides especially in rural 
Asia where agriculture is the main source of livelihood for many. Deliberate self harm by 
consumption of these insecticides is prevalent as these compounds are cheap and 
easilyaccessible. The cornerstone of management remains supportive treatment, 
anticholinergics and reactivators of acetylcholinesterase. A practice routinely carried out 
in many of the developing countries is gastric decontamination procedures, to minimize 
the amount and duration of contact of the toxin with the GI mucosa. The hypothesis being 
that this may decrease the potential life threatening complications of the toxin. The 
various methods of gastric decontamination that have been carried out are induce 
vomiting with ipecac, gastric lavage and activated charcoal. Out of these, induced 
vomiting with ipecac has proven to be harmful and hence is not used in clinical practice. 
The role of gastric lavage and activated charcoal is still being debated in view of lack of 
good quality studies. There is scanty evidence for the benefit of this procedure. Studies 
done till now have not shown benefit and have reported various complications associated 
with the procedure. The use of this procedure has decreased in Western countries. 
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The current role of gastric lavage in OP poisoning is unclear. There is also a scarcity of 
proper and well done studies with adequate sample size evaluating the efficacy of gastric 
lavage in organophosphorus poisoning. However it is still considered the standard of care 
and a legal requirement in many countries, including India. In Indian setting patients take 
significant amounts of highly toxic OP which cause life threatening complications. OP 
compounds are liquid and removal of even a small amount may have a possible benefit. 
In this setting of lack of evidence for the procedure, this study is planned to assess the 
“proof of concept” for potential benefit of gastric lavage in acute organophosphate 
poisoning based on the idea that if gastric lavage is effective then the amount of OP will 
be undetectable at the end of the procedure and a significant amount of OP would have 
been removed during the lavage process. This study aims to answer the following 
questions: 
1. Does gastric lavage remove organophosphate compound from the stomach? 
2. How many cycles of gastric lavage are required to remove organohosphate from the 
stomach? 
3. What are the factors that determine the concentration of organophosphate in the stomach 
at presentation ? 
 
Such a study has not been conducted based on our review of the published literature and it may 
help us understand better the role of gastric lavage in organophophate poisoning. 
 
 
45 
 
6 METHODOLOGY 
6.1 SAMPLE AND SETTING 
The study was conducted during the period April 2015 to June 2016 in Christian Medical 
College, Vellore. All patients who presented to adult emergency department with 
organophosphate poisoning within 6 hours of consumption of the compound and  
fulfilling the inclusion criteria were included in the study. The details of the study and the 
procedure of gastric lavage was clearly explained to the patient and their close relatives in 
simple terms and in a language they understood. They were also given an information 
sheet in their native language.  In eligible patients who were willing to participate in the 
study, a written consent was obtained and in the case of an obtunded patient, consent was 
obtained from a close relative accompanying the patient.  When consent was obtained 
from relative, re-consent was obtained from the participant after recovery. 
 
6.2 STUDY DESIGN 
This is a prospective observational study conducted as a pilot in patients presenting with 
acute organophosphate poisoning with 6 hours of consumption to assess the efficacy of 
gastric lavage in removing the organophosphate from the stomach. 
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6.3 SAMPLE SIZE 
As there are no studies done in CMC or available in literature which have looked at the 
amount of organophosphate removed from the stomach by gastric lavage, sample size 
calculation was not possible for this study. Hence, after discussion with the statistician a 
pilot study on 40 patients was proposed. 
 
6.4 PARTICIPANTS 
Eligibility criteria 
The study participants were enrolled from the Accident and Emergency department, 
Christian Medical College,Vellore who fulfilled the following inclusion criteria: 
 
Inclusion criteria: 
1. Patients above 18 years of age 
2. History of consumption of organophosphate within 6 hours of presentation and 
who are to undergo gastric lavage 
 
Exclusion criteria: 
1 Patients less than 18 years 
2 Patients with no known OP compound 
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Case Ascertainment: 
 
1. Patients who present with alleged history of organophosphorous poisoning with an 
identified compound based on self-report or bringing the pesticide container or 
pamphlet of the consumed pesticide. 
 
2. Patients who present with alleged history of unknown pesticide with typical 
toxidrome of cholinergic crises, and low butrylcholinesterase levels and in whom 
the compound was identified later by the container that was brought to the hospital 
by the relatives. 
 
Patients who had consumed mixed compounds of organophosphorus with pyrethroids 
were not excluded. Pregnant women were also included in the study as OP poisoning can 
occur in any person and gastric lavage is a standard of care in India. 
 
6.5 DATA AND SAMPLE COLLECTION 
After fulfillment of inclusion criteria and informed consent, participants were  enrolled in 
the study. The recommended treatment guidelines for management of organophosphorus 
poisoning were followed according to the discretion of the treating physician. 
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The data was collected by the principal investigator and was entered in the clinical 
research form.  The clinical proforma consisted of the following specific details : 
1. Compound characteristics – class, quantity and combination with pyrethroids 
2. Time to presentation to CMC, Vellore 
3. Treatment received elsewhere prior to admission  – Gastric lavage, Atropine and 
Pralidoxime 
4. Severity at presentation (by Namba scale) 
5. Outcomes – Dose of atropine required and duration, Mechanical ventilation and 
duration, intermediate syndrome and duration, need for ICU admission and duration, 
complications of gastric lavage like aspration pneumonia, oesophageal or gastric 
perforation, laryngospasm, arrhythmias  and cardiac arrest. 
 
After hemodynamic stabilization of the patient in accident and emergency department, a 
10ml blood sample was withdrawn for the routine tests and was also sent for estimation 
of OP compound and its concentration. Then, as per standard protocol a nasogastric tube 
was inserted and stomach contents aspirated. 10 ml of the gastric aspirate was collected 
in a bottle labelled ‘A’, with the total volume of aspirate labelled over it. Following 
which, gastric lavage was performed by the principal investigator by instilling 200ml of 
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tap water through NG tube and then re-aspirating  till the samples were clear and there 
was no smell of organophosphate (78). During each cycle, the colour and the smell of the 
aspirate was noted. 10ml sample from each cycle  of gastric lavage was collected in 
bottles labelled B, C, and D with total volume of  each gastric lavage labelled over each 
bottle.  After the lavage, another 10ml blood sample was collected to measure the serum 
concentration  of  OP in blood. The gastric aspirate and blood samples were then sent to 
clinical biochemistry lab for HPLC testing. 
6.6 LABORATORY ANALYSIS 
The OP compounds for which HPLC testing can be done in our laboratory in Christian 
Medical College, Vellore  are 
 Acephate 
 Chloropyriphos 
 Dimethoate 
 Malathion 
 Methylparat 
 Monocrotophos 
 Phorate 
 Profenophos 
 Triazophos 
 Quinalphos 
 
 
50 
 
These assays have been established for earlier research studies by the clinical 
biochemistry co-investigators of the study. 
HPLC of  Hydrophilic OP compounds 
200µl of plasma was taken in a 1.7ml vial and 400µl of acetonitrile added; the mixture 
was vortexed for 30 seconds. The vial was then centrifuged at 13000 RPM. 300µl of 
supernatant was carefully separated into a glass vial, and evaporated to dryness at 37C 
by blowing down with an inert gas (nitrogen). The dried residue was reconstituted with 
200µl mobile phase. 
 
HPLC analysis for hydrophilic OP compounds was performed on a Perkin Elmer Series 
200 HPLC system with a 25 cm x 4.6mm, 5µm Supelco, Discovery HS C18 column 
(Supelco, Sigma Aldrich). The mobile phase used for hydrophilic compounds was  30% 
acetonitrile at a flow rate of 1 mL/min. Run time was set for 30 minutes and 100µl of 
extracted sample injected onto the column. The detector used was a Perkin Elmer diode 
array detector at 200nm 
 
HPLC of  Lipophilic OP compounds 
Short solid phase C18 extraction mini columns from Phenomenox (USA) was used for 
separation and clean-up of samples. One ml of methanol added to the C18 column for 
conditioning. A vacuum manifold was then  used for draining the column. Each column 
was equilibrated using 1ml water, and then drained using negative pressure. One ml of 
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plasma was acidified with 20μl of perchloric acid, centrifuged at 13000 RPM and then 
added to the column. It was allowed to stand and then drained slowly using vacuum. One 
ml of 5% methanol added to the column and washed and drained. The OP compounds 
were then eluted using one ml 100% methanol. This eluent was collected and evaporated 
to dryness under nitrogen and the residue  reconstituted in 200ul mobile phase and 100 μl 
of this  injected to the HPLC system. 
 
HPLC analysis for lipophilic OP compounds was performed on the same HPLC system 
with a C18 column (Supelco, Sigma Aldrich). The mobile phase used for lipophilic 
compounds was  80% methanol at a flow rate of 1 mL/min. Run time was set for 30 
minutes and 100ml of extracted sample was injected onto the column . The detector used 
is a diode array detector set at 240nm. 
 
Monocrotophos between day assay variation, n=12, mean= 40.14mcg/ml, SD=1.17, 
%CV=2.91 
Quinalphos between day assay variation, n=8, mean=4.96mcg/ml, SD=0.22, 
%CV=4.07% 
 
The patients were followed up daily for the first week to assess the clinical outcomes 
during their stay in the hospital and at the time of discharge . 
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7 STATISTICAL ANALYSIS 
Data will be entered in EPIDATA software and cleaned using SPSS software using 
Frequency distributions, Box-Cox plots and Histogram. The estimate of OP compound 
was presented with point estimate with 95% CI. Paired t test was done to test whether 
there was difference between the concentration of OP before and after lavage. The 
number of cycles of gastric lavage was estimated using appropriate distribution such as 
Normal or Poison, based on the distribution. Then, the estimate and the 95% CI was  
presented. Association between certain determinant variables with the amount of OP in 
the stomach was done using multivariable regression analysis. 
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8 FUNDING AND APPROVAL 
8.1 SOURCE OF FUNDING 
A FLUID research grant was approved from the institution for the purpose of this study. 
The funds were used for the HPLC testing of the gastric aspirates. 
 
8.2 INSTITUTIONAL RESEARCH BOARD APPROVAL AND ETHICAL 
CONSIDERATIONS 
The research proposal for gastric lavage in OP poisoning  was discussed by the 
Institutional Review Board in 2015 and approval was obtained [IRB Min No: 9141 
dated12.11.2014 ].  There were no ethical issues related to this study. Institutional review 
board approval was obtained for the procedures. 
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9   RESULTS 
9.1 PART – A  CLINICAL PROFILE OF ORGANOPHOSPHATE  
POISONING 
9.1.1 DEMOGRAPHIC CHARACTERISTICS 
 
The study was conducted during the time period April 2015 – June 2016 and included 42 
patients with organophosphate poisoning who presented to the accident and emergency 
department of Christian Medical College Hospital, Vellore within 6 hours of 
consumption. The mean age (±S.D) of the participants was 30.5 years (±12.74 years) 
ranging between 15 to 70 years. There was a slight male preponderance, 22 (52.4%) as 
compared to females 20(47.6%). Out of the 42 participants, 26(61.9%) brought the 
pesticide container and 23(54.8%) presented with cholinergic crises. The mean 
pseudocholinesterase level was 2128.45 (Lowest – 71 and Highest – 9928). Based on the 
Namba severity score 18 (42.9%) of the patients presented with severe poisoning.   
(Table 5) 
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Table 5: Baseline Characteristics 
Profile Details 
Total participants 42 
Age(mean ± S.D) years 30.5 ±12.7 
Male : female ratio(percentage) 22 (52.4%): 20(47.6%) 
Compound identified (%) 
Pesticide container 
Pamphlet 
Oral report 
33(78.6%) 
26 
7 
9 
Pyrethroid combination with OP 9/33 (27.3%) 
S.Pseudocholinesterase level 2128.45 ± 2846.9 
Severity of Poisoning (Namba scale) 
Latent 
Mild 
Moderate 
Severe 
 
6(14.3%) 
14(33.3%) 
4(9.5%) 
18(42.8%) 
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9.1.2 COMPOUND CHARACTERISTICS 
         Organophosphorus compound (OP) was identified in 33(78.6%) patients, by the 
pesticide container in 26 cases and by the pamphlet in 7 cases. In the remaining, the 
diagnosis of organophophorus poisoning was made by a history of OP consumption with 
a typical cholinergic syndrome  and  low butrylcholinesterase level. 
In the majority of cases only OP compound was ingested. The most common OP 
compound was triazophos 6/33 (18.2%), followed by chlorpyriphos 5/33 (15.15%). There 
were 3 cases each of monocrotophos, dimethoate and dichlorvas. The remaining 5 cases 
were due to Malathion, methylparathion, penthoate, quinalphos and ethion. 27.3% of 
patients had consumed mixed compounds, a combination of organophosphorus and 
pyrethroids. The most common pyrethroids were cypermethrin and deltamethrin, 4 cases 
each and were used in combination with profenophos or triazophos. 
The majority of OP compounds were diethyl OP compounds (45.5%), followed by 
dimethyl group (39.4%) and S-alkyl OP compounds (12.1%).  The majority of OP 
compounds were WHO class I compound (51.5%), followed by class II (30.3%) and then 
WHO Class III (18.2%). ( Figure 4,5) 
Of the identified OP poisoning cases, 18.2% were due to water soluble compounds and 
81.8% were due to fat soluble OP compounds. The water soluble compounds identified 
were monocrotophos and dimethoate while the majority was lipid soluble compounds 
like chlorpyriphos, triazophos, methylparathion and prophenophos.( Table 6) 
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Figure 4: Different types of chemical compounds ingested 
 
 
Figure 5: WHO classification of ingested OP compounds 
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Table 6: Frequency of Individual compounds 
Compound Number WHO class Type 
Triazophos 6 I Diethyl 
Chlorpyriphos 5 II Diethyl 
Phorate 4 I Diethyl 
Prophenophos 4 III S-alkyl 
Dichlorvas 3 I Dimethyl 
Dimethoate 3 II Dimethyl 
Monocrotophos 3 I Dimethyl 
Malathion 1 III Dimethyl 
Methylparathion 1 I Dimethyl 
Penthoate 1 II Dimethyl 
Quinalphos 1 II Diethyl 
Ethion 1 III Others 
 
9.1.3 TREATMENT RECEIVED PRIOR TO PRESENTATION 
         Only patients who presented to our hospital within 6 hours of consumption of OP 
compounds were included in this study. The majority had received prior medical aid 
before reaching our centre (73.8%).(Figure 6) The mean time to presentation to any 
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medical centre after consumption of OP compound was 1.35 hours and the mean time to 
admission in our hospital was 2.9 hours. Therefore the patients included in this study 
presented without much delay to our hospital. The mean amount of OP consumed as 
reported by the patients was 64.47ml ± 51.59. Two-third (71.4%) of the patients had 
already undergone a decontamination procedure before reaching our hospital with gastric 
lavage being performed in 64.3% and forced emesis in 14.3%. Activated charcoal was 
administered in a minority of the patients.(Figure 7) 
 
Figure 6: Percentage of patients who underwent prior decontamination procedures 
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Figure 7: The various gastric decontamination procedures that were carried out 
before reaching our hospital 
 
The majority of the patients received atropine (52.4%) and a minority received 
pralidoxime (11.9%) before reaching our hospital. 93.3% of patients had prior treatment 
in the government hospital. 
 
9.1.4 CLINICAL TOXIDROMES AT PRESENTATION    
         The patient population in our study presented with typical symptoms of OP 
poisoning with vomiting (83.3%), salivation (61.9%), sweating (23.8%), breathlessness 
(33.3%) and altered sensorium (50%). (Table 7)The majority of the patients also 
14.30% 
6 
64.30% 
27 
2.40% 
1 
0.00% 
10.00% 
20.00% 
30.00% 
40.00% 
50.00% 
60.00% 
70.00% 
Forced emesis Gastric lavage Activated charcoal 
Prior decontamination 
procedures 
 
 
61 
 
presented with characteristic signs of OP poisoning with 35.7% of them having pinpoint 
pupils at admission and 35.7% having GCS < 10/15. (Table 8) Thus, patients in the study 
had a typical toxidrome of OP poisoning. 
 
Table 7: Clinical symptoms at admission in patients with OP poisoning 
Toxidrome Number of patients (%) 
Vomiting 35 (83.3%) 
Salivation 26 (61.9%) 
Sweating 10 (23.8%) 
Defecation 8 (19.0%) 
Urination 6 (14.3%) 
Lacrimation 5 (11.9%) 
Seizures 7 (16.7%) 
Breathlessness 14 (33.3%) 
Altered sensorium 21 (50.0%) 
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Table 8: Clinical signs at admission in patients with OP poisoning 
Clinical signs Number of patients%(or Mean ±S.D) 
GCS, n (%) 
15/15 
<10/15 
 
21(50.0%) 
15(35.7%) 
Pupil size, n (%) 
Pinpoint 
Dilated 
Normal (2-5mm) 
 
15(35.7%) 
0 
27(64.3%) 
Heart rate, (mean± S.D) 105.98  ± 22.2 beats per minute 
Blood pressure, (mean± S.D) 110.95±14.1 / 70.48±13.4mm Hg 
Mean respiratory rate,(± S.D) 25.48 ±8.3 breaths per minute 
O2 saturation, (mean± S.D) 92.69 ±8.6% 
Blood sugar, (mean± S.D) 152.21±52.5mg% 
Fasciculation’s present, n (%) 3 (7.1%) 
Single breath count, (mean± S.D) 
Mean 
Could not be assessed 
 
24.5 ± 9.7 
18(42.9%) 
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9.1.5 CLINICAL OUTCOMES  
         During their course in the hospital, 47.6% of the patient’s required ICU admission, 
47.6% mechanical ventilation and 16.7% developed intermediate syndrome. Majority 
required atropinisation with a mean dose of 219 mg and for a mean duration of 3.4 days. 
The mean duration of mechanical ventilation was 7.1 days. A few patients required 
tracheostomy for prolonged mechanical ventilation. The most common infective 
complication was nosocomial pneumonia (14.3%) and the mean duration of 
hospitalization was 7.7 days.( Table 9) 
Table 9 : Clinical outcomes of the OP poisoning patients 
Clinical outcome Number of patients with % or( Mean 
± S.D) 
Intermediate syndrome, n (%)  
Present 
Duration 
 
7 (16.7%) 
7.43 ± 8.3 days 
ICU admission, n (%) 
Present 
Duration 
 
20 (47.6%) 
8.35 ± 8.3 days 
Mechanical ventilation, n (%) 
Present 
Duration 
 
20(47.6%) 
7.0 ± 8.37 days 
Tracheostomy required, n (%) 2(4.76%) 
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Figure 8: The final outcome in patients with OP poisoning 
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6(14.3%) 
Atropine Required, n (%) 
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Duration, mean ± S.D 
38(90.5%) 
213.6 ± 253.2 mg 
3.4 ± 2.1 days 
Hospitalization duration, 
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Death, n (%) 
(Causes of death) 
2(4.76%) 
(1 -infection , 1-cardio respiratory arrest) 
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Majority of the patients in the study had a good clinical outcome with 88.10% being 
discharged alive. 11.9% had a poor outcome (2 patients died and 3 were discharged 
against medical advice).( Figure 8) 
9.2 PART – B GASTRIC LAVAGE AND OP POISONING 
SECTION 1 
9.2.1 PERFORMANCE OF GASTRIC LAVAGE 
         There were a total of 42 organophosphate poisoning patients who underwent gastric 
lavage in accident and emergency department and their samples were analysed. 97.6 %    
(41/42) of the gastric lavages were done by the primary investigator and 1 done by 
another PG registrar. The procedure included a first gastric aspirate and subsequent 
cycles of gastric lavage. The volume of fluid administered with each cycle was 200 ml of 
tap water.(Table 10) 
First gastric aspirate(GA) - the first aspirate after insertion of the nasogastric tube 
Gastric lavage(GL) cycles 1-3 - refers to the respective cycles of gastric lavage 
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Table 10: The baseline characteristics of the gastric lavage samples 
 Number 
of samples 
Mean volume 
aspirated ±S.D 
ml 
Colour of 
aspirate –  
Clear, n (%) 
Smell of OP 
present, n (%) 
First GA 27* 64.7 ±117.7 3(11.1%) 27(100%) 
GL cycle 1 42 189.7 ±87.7 11(26.2%) 35(83.3%) 
GL cycle 2 42 214.8 ±78.7 25(59.5%) 16(38.1%) 
GL cycle 3 41** 231.4 ±114.7 39(95.1%) 1(2.4%) 
* In 15 patients, there was no first gastric aspirate 
** There was 1 missing 3
rd
 lavage sample 
 
Majority (27/42) had a significant first aspirate from the stomach with a mean volume of 
64.7ml. The termination of gastric lavage was assessed by the clearing up of the aspirate 
and disappearance of OP smell from the lavage. All the patients had the smell of OP in 
the first gastric aspirate with gradual disappearance of smell with each cycle of  lavage 
(Gastric aspirate- 100%, cycle 1-83.3%, cycle 2-38.1%, Cycle 3- 2.4%). All the patients 
required 3 cycles of lavage to get clear aspirate from the stomach. Gastric lavage was 
performed by administration of 200ml of tap water into the stomach through the 
nasogastric tube. Thus, the efficacy of the lavage is indicated by the equality in the 
volume aspirated from the stomach and that injected into the stomach (Mean volumes 
aspirated Cycle 1-190 ml, cycle 2-215 ml, cycle 3-231 ml). 
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9.2.2 COMPLICATIONS OF GASTRIC LAVAGE  
 
 
Figure 9: Gastric lavage and its complications 
 
         There were very few complications of the gastric lavage procedure (7.1%).(Figure 
9) Only 3 patients of the 42 who underwent gastric lavage developed aspiration 
pneumonia. There were no patients who developed any other procedure related 
complications like laryngospasm, esophageal perforation, arrhythmias or cardiac arrest. 
Thus, indicating that if the procedure is done with the right technique then procedure 
related complications are minimal. 
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SECTION 2 
9.2.3 LAB ANALYSIS OF GASTRIC LAVAGE SAMPLES 
9.2.3.1 DETECTION OF OP IN STOMACH AND ITS DETERMINANTS 
         There were 42 patients who underwent gastric lavage; however 8 patients’ gastric 
lavage samples could not be analyzed due to lack of pure standards for performance of 
HPLC for three compounds: phorate, dichlorvas and ethion. Out of the remaining 34 
patients, in majority of them OP compound was detectable in the gastric lavage samples 
in 24 patients (70.6%) and in 10 patients (29.4%) it was not detectable. The lack of 
detection of OP in the above 10 cases probably indicates the absence of OP in the 
stomach.(Figure 10) 
 
Figure 10:The study population which underwent gastric lavage 
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9.2.3.2 OP COMPOUNDS DETECTED IN THE STOMACH  
         Patients with lack of standards for OP detection (8 cases) were excluded from 
analysis. Thus, out of the 34 patients whose gastric samples could be analysed there were 
10 cases in whom OP could not be detected, while in 24 OP could be detected in 
stomach. Of the 24 patients with detectable OP compounds, the frequencies of the 
various OP compounds that could be detected in the stomach and that could not be 
detected in the stomach are listed below in Table 7. The most common detectable OP 
compound was chlorpyriphos (41.7%), followed by triazophos (20.8%), methylparathion 
(12.5%) and prophenophos (12.5%). 
None of the hydrophilic compounds that were ingested like monocrotophos and 
dimethoate could be detected in the stomach while nearly all lipophilic OP compounds 
(88.5%) were detected in the stomach. It is very likely that the hydrophilic compounds 
were eliminated from the stomach rapidly by the time of performance of gastric lavage 
due to mucosal absorption or passage into the small intestine.(Table 11) 
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Table 11: The various OP compounds based on their detectability in the stomach 
COMPOUND OP DETECTED (24) OP NOT DETECTED (10) 
LIPOPHILIC   
Chlorpyriphos 10(41.7%) 0 
Triazophos 5(20.8%) 1 (10%) 
Prophenophos 3(20.8%) 0 
Methylparathion 3(12.5%) 0 
Malathion 1(4.2%) 1 (10%) 
Quinalphos 1(4.2%) 1 (10%) 
HYDROPHILIC   
Monocrotophos 0 3 (30%) 
Dimethoate 0 3 (30%) 
UNKNOWN 1 (4.2%) 1 (10%) 
 
9.2.3.3 OP DETECTED IN THE FIRST GASTRIC ASPIRATE  
         There were totally 27 patients with a first gastric aspirate sample, out of which 17 
had a prior gastric lavage and 10 had no prior gastric lavage. 64.7% of patients with prior 
gastric lavage had OP compound detected in first gastric aspirate  in comparison to 60% 
in those who did not have prior lavage and this differencewas not statistically different ( p 
value - 0.563). The presence of OP compound in the stomach despite prior lavage 
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indicates that either prior gastric lavage was not properly performed or was not 
completely effective in removing the OP from the stomach.(Figure 11,12) 
 
Figure 11: In patients with a first gastric aspirate, the percentage with detectable 
OP in the stomach even after prior gastric lavage 
 
Table 12: Correlation of OP detected in first gastric aspirate with prior gastric 
lavage 
 OPdetected(n%) OP not detectedn(%) p value 
Prior gastric lavage 11 (64.7%) 6(60.0%) 0.563 
No prior gastric lavage 6(35.3%) 4(40.0%)  
 
64.70% 
60% 
0% 
10% 
20% 
30% 
40% 
50% 
60% 
70% 
80% 
90% 
100% 
Prior gastric lavage No prior gastric lavage 
% No OP detected 
% OP detected 
 
 
72 
 
9.2.3.4 MEAN AMOUNT OF OP REMOVED FROM THE STOMACH IN 
THOSE WITH A PRIOR GASTRIC LAVAGE  
         Out of the 24 patients with detectable OP in the stomach, 15 had a prior gastric 
lavage and 9 did not have. There was no significant difference between the median 
amount of OP removed from the stomach in those with a prior gastric lavage (131.7 
micrograms) compared to without prior gastric lavage (135 micrograms).(Table 13) 
Table 13: Correlation of mean amount of OP removed from stomach and prior 
gastric lavage 
 N Mean amount of 
OP removed 
(mean ± S.D) mcg 
Median (IQR) p 
value 
Prior GL 15 1169.1± 2561.1 131.7(28.1,843.0) 0.321 
No prior GL 9 7396.1± 11009.0 135.0(76.3,20461.6)  
IQR : Interquartile range 
9.2.3.5 CORRELATION BETWEEN LAG TIME AND DETECTION OF OP 
IN THE FIRST GASTRIC ASPIRATE 
Lag time 1: Time to first hospital contact 
Lag time 2: Time to presentation to our hospital 
Out of the 42 patients who underwent gastric lavage, 28 patients presented to a medical 
centre after consumption of OP compound within 1 hour and 14 presented after 1hour. In 
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those who came within 1 hour, 39.3% had detectable OP in the first gastric aspirate as 
compared to 36.8% in those who  came after 1 hour of consumption of OP. Four patients 
came to our hospital within 1 hour of consumption of OP compound while the majority 
(90.5%) presented after 1 hour. Lag time had no significant impact in the detection of OP 
compound in the stomach. Even patients who came after 1 hour of consumption of OP 
had detectable OP in the stomach and there was no significance statistical difference in 
the detection of OP in the first gastric aspirate whether patient came to the first hospital 
or to our hospital within 1 hour or later (Lag time 1 p=0.822,  lag time 2 p=0.628). 
(Figure 12,13; Table 14,15) 
 
Figure 12:Correlation between time to presentation to first hospital and detection of 
OP compound in the first gastric aspirate 
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Table 14: Time to presentation to first hospital versus detection of OP compound in 
the first gastric aspirate 
Lag time1 OP detected 
n(%) 
OP not detected 
n(%) 
p value 
<=1 hour 11(39.3%) 17(60.7%) 0.822 
>1 hour 5(35.7%) 9(64.3%)  
 
 
 
Figure 13: Correlation between time to presentation to CMC and detection of first 
gastric aspirate 
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Table 15: Time to presentation to CMC versus detection of first gastric aspirate 
Lag time 2 OP detected 
n(%) 
No OP detected 
n(%) 
p value 
<= 1 hour 2(50%) 2(50%) 0.628 
>1 hour 14(36.8%) 24(63.2%)  
 
9.2.3.6 MEAN AMOUNT OF OP REMOVED FROM THE STOMACH IN 
RELATION TO LAG TIME 2 
         The mean amount of OP removed from the stomach based on the patient’s time to 
presentation to our hospital after consumption of OP compound was studied. In the 
patients who presented to CMC at 1-2 hours and 3-4 hours had removal of 3 mg and 7 mg 
of OP with gastric lavage. In the four patients who presented at 5-6 hours after ingested a 
mean of only 0.07 mg was removed by gastric lavage. It appears that by 5-6 hours after 
ingestion the amount of OP in the stomach has declined.(Table 16) 
Table 16: Mean OP removed from the stomach in relation to time to presentation to 
our hospital after consumption of the compound 
LAG TIME 2 N Mean Amount of 
OP removed (mcg) 
1-2  hours 13 2852.2 
3-4 hours 7 6678.9 
5-6 hours 4 67.8 
 
 
76 
 
9.2.3.7 FACTORS THAT AFFECT THE PRESENCE OF OP IN THE 
STOMACH 
 
         The determinants of the presence of OP in the stomach were studied by comparing 
patients with detectable OP and those without detectable OP in the stomach. There were a 
total of 34 patients with standards for analysis, Of these the total number of patients with 
detectable OP in the stomach were 23 and those with no OP in the stomach were 11. 
There was no significant association between the following factors and detection of OP in 
the stomach: (i) the amount of OP consumed, (ii) lag time or (iii) prior decontamination 
procedures. 84.6% (22/26) of patients who had ingested hydrophilic compounds had 
detectable compound in the stomach while none of the six hydrophilic compounds could 
be identified in the stomach. Due to the small numbers statistical analysis was not 
performed for the difference in detection of OP compounds in the stomach between 
hydrophilic and lipophilic compound ingestion.(Table 17) 
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Table 17: Determinants of OP in the stomach 
FACTORS 
DETERMINING 
OP  IN 
STOMACH 
 
OP DETECTED IN 
STOMACH(23) 
n (%) 
Median(IQR) 
OP NOT DETECTED 
IN STOMACH(11) 
n (%) 
Median(IQR) 
p 
value 
Amount of OP 
consumed(ml) 
50.0( 35.0,100.0) 60.0(25.0,100.0) 0.984 
Lag time 1,(hrs) 
Lag time 2,(hrs) 
1.0(0.5,2.0) 
2.0(2.0,3.0) 
1.0(1.0,1.5) 
2.5(1.5,5.5) 
0.252 
0.852 
Prior 
decontamination 
procedures 
Forced emesis 
Gastric lavage 
17(73.9%) 
 
 
3(13.0%) 
14(60.9%) 
8(72.7%) 
 
 
2(18.2%) 
8(72.7%) 
1.000 
 
 
1.000 
0.705 
OP compounds 
Lipophilic 
Hydrophilic 
Unknown 
 
22(95.7%) 
0 
1(4.3%) 
 
4(36.4%) 
6(54.5%) 
1(9.1%) 
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9.2.4 AMOUNT OF OP REMOVED FROM THE STOMACH BY GASTRIC 
LAVAGE: TOTAL AND WITH EACH CYCLE 
9.2.4.1 MEAN TOTAL AMOUNT OF OP REMOVED FROM THE 
STOMACH BY GASTRIC LAVAGE 
         The total amount of OP removed by gastric lavage was 3946.7 (±7786.3) 
micrograms among patients who had an initial gastric aspirate and 2619.3 mg (±7178.8) 
micrograms in those who did not have an initial gastric aspirate. In patients with an initial 
gastric aspirate, this part of the procedure removed 91.3% of OP.  In these patients Cycle 
1, 2 and 3 removed 5.3%, 2.4% and 1% of OP respectively. In patients who did not have 
an initial gastric aspirate the cycle 1 aspirate removed 88.1% of OP. In these patients 
Cycle 2 and 3 removed 11.5% and 0.4 % respectively.(Table 18) 
Table 18:Mean amount of OP removed from the stomach during gastric lavage 
 Mean amount of OP removed in micrograms ( S.D) 
 Gastric aspirate present Gastric aspirate absent 
 n=16 n=8 
Gastric aspirate 3604.6 ± 6997.5 0 
Cycle 1 210.4 ± 664.7 2307.2 ± 6370.9 
Cycle 2 93.4 ± 324.3 300.6 ± 802.0 
Cycle 3 38.4 ± 130.6 11.6 ±11.9 
Total 3946.7 ±7786.3 2619.3 ±7178.8 
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9.2.4.2 PROPORTION OF OP REMOVED IN EACH CYCLE OF GASTRIC 
LAVAGE  
         The proportion of OP removed from the stomach between two groups was studied. 
Group 1: Patients with a detectable OP in the first gastric aspirate (n=16) 
Group 2: Patients with no gastric aspirate (n=8) 
In patients with first gastric aspirate the mean proportion of OP removed by the first 
gastric aspirate alone was 79.38%, while in patients without the first aspirate and the 
mean proportion of OP removed by the first cycle of gastric lavage was 57.69%. Thus, 
gastric lavage was most effective in removing the OP from the stomach with the first 
gastric aspirate and the first cycle of gastric lavage. There was a declining proportion of 
OP with every cycle of gastric lavage.(Figure 14,15) 
 
Figure 14: Proportion of OP removed from the stomach in those with gastric 
aspirate 
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Figure 15: Proportion of OP removed from the stomach in those with no gastric 
aspirate 
9.2.4.3 CORRELATION OF AMOUNT OF OP REMOVED FROM THE 
STOMACH WITH CYCLE OF LAVAGE IN THOSE WITH A 
GASTRC ASPIRATE 
 
         The maximum amount of OP removed was  in the first gastric aspirate. The 
proportion of  OP removed by the first gastric aspirate was compared  with  1
st
, 2
nd
 and 
3
rd
 cycle of lavage. The decline in the amount of OP on comparing the first gastric 
aspirate with 1
st
 gastric lavage was -67.9 (p value <0.001), first gastric aspirate with 
second lavage was -72.8 (p value <0.001) and first gastric aspirate with third lavage was -
76.8 ( p value <0.001) which was statistically significant.(Table 19) 
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Table 19: Correlation of amount of OP removed in first gastric aspirate versus the 
subsequent cycles of gastric lavage 
 
Gastric lavage B coefficient 95% CI p value 
Lower Upper 
First aspirate 
versus 1
st
 cycle GL 
-67.9 -82.6 -53.2 <0.001 
First aspirate 
versus 2
nd
 cycle GL 
-72.8 -86.5 -59.2 <0.001 
First aspirate 
versus 3
rd
 cycle GL 
-76.8 -88.4 -65.2 <0.001 
 
In those without a gastric aspirate, comparison was done between 1
st
 cycle of GL with 2
nd
 
and 3
rd
 cycle. Decline in the amount of OP in the stomach  with 1
st
 cycle of gastric lavage 
as compared to 2
nd 
 was -28.5 which was not statistically significant (p value 0.063). 
However, on comparing 1 st cycle of lavage with 3
rd
 cycle, the decline was -44.6 (p value 
<0.001) which was statistically significant.(Table 20) 
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Table 20: Correlation of amount of OP removed in first gastric lavage versus the 
subsequent cycles of gastric lavage 
Gastric lavage B coefficient 95% CI p value 
Lower Upper 
1
st
 cycle versus 2
nd
 
cycle GL 
-28.5 -58.5 -1.6 0.063 
1
st
 cycle versus 3
rd
  
cycle GL 
-44.6 -69.5 -19.8 <0.001 
     
 
 
9.2.4.4 PATIENTS WITH NO DETECTABLE OP IN STOMACH AFTER 
EACH CYCLE OF GASTRIC LAVAGE 
         With each cycle of gastric lavage, there was increasing proportion of patients who 
had no detectable OP in the stomach: first cycle- 13.04%; second cycle- 34.78% and third 
cycle- 47.82%. This shows that gastric lavage was effective in removing OP from the 
stomach. However, even after 3 cycle of gastric lavage there were more than 50% of 
patients who still had detectable OP in the stomach.(Figure 16) 
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Figure 16: Number of patients with no detectable OP after each cycle of gastric 
lavage 
 
9.2.4.5 ESTIMATE OF MEAN AMOUNT OF EACH OP COMPUND 
REMOVED FROM THE STOMACH 
         The common OP compounds that could be identified in the gastric lavage samples 
were chlorpyriphos (10), triazophos (5) and methylparathion (3). The mean amount of 
each of the compounds removed by gastric lavage was: Chlorpyriphos- 653.4mcg (+0.65 
mg); Triazophos- 9275.2 (+9.2 mcg) and Methylparathion- 6916.13 (+7 mcg) 
respectively (See Table 16). Therefore the mean amount of OP removed ranged from 
approximately 0.5 mg (500 mcg) -10 mg (10,000 mcg) 
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The estimated amount of OP ingested (gms) by the patients was calculated by 
multiplication of the concentration of OP on the packet and the report of the volume 
ingested by the patient (See Table 18). The mean reported amount of Chlorpyriphos 
ingested (5 patients) was 8.6±3.2 g. In the two patients who ingested Triazophos, 
Propenophos and Methylparathion the average amount ingested was 39.5 g, 17.5 g and 2 
g respectively. Therefore the quantity of OP ingested ranged from 2 grams (2000 mg) to 
40 g (40,000 mg).(Table 21) 
Therefore it is clear that the amount ingested is in grams but the amount removed by 
gastric lavage is in mg. For example in Chlorpyriphos the average amount ingested was 
8.6 g but the average amount removed was 0.0006 g (0.6 mg). Therefore the proportion 
of ingested Chlorpyriphos removed by gastric lavage is <1%. 
This could be demonstrated for 4 compounds chlorpyrifos, Triazhophos, Propenophos 
and Methylparathion. From this analysis it is clear that although gastric lavage removes 
measurable amount of OP from the stomach, the amount removed is relatively small in 
relation to the amount ingested.(Table 22) 
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Table 21: : Mean amount of each OP compound removed from stomach 
OP Compounds N Mean amount removed in mcg ± 
S.D 
Chlorpyriphos 10 653.4 ±388.5 
Triazophos 5 9275.2 ±5525.1 
Prophenophos 3 120.7 ±61.0 
Methlyparathion 3 6916.1 ±6811.6 
Quinalphos 1 331.7 ± 0.0 
Malathion 1 72.3 ±0.0 
 
Table 22: Estimated amount of OP ingested in those who had identified the 
compound 
OP compounds Historical identification of OP Estimated amount 
ingested (grams) 
Chlorpyriphos 5 8.6  ±3.2 
Triazophos 2 39.5 ± 0.5 
Prophenophos 2 17.5 ± 2.5 
Methlyparathion 1 2 ±0 
Quinalphos 0 - 
Malathion 0 - 
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9.2.4.6 MEAN PROPORTION OF OP REMOVED FROM THE STOMACH FOR 
EACH COMPOUND  
(Figure 14) 
 
Figure 17: Proportion of OP removed from the stomach for each compound 
 
There were totally 16 OP compounds detectable in the first gastric aspirate, out of which 
there were 6 cases of chlorpyriphos, 5 of triazophos and 3 of each methylparathion and 
prophenophos. Similar to the analysis of all OP patients together, the patients with 
ingestion of each of the four compounds showed a similar declining trend with each cycle 
of gastric lavage and the maximum proportion was removed with the first gastric 
aspirate.(Figure 17) 
0.00% 
10.00% 
20.00% 
30.00% 
40.00% 
50.00% 
60.00% 
70.00% 
80.00% 
90.00% 
100.00% 
First gastric 
aspirate 
Cycle 1 Cycle 2 Cycle 3 
Chlorpyriphos Triazophos Methylparathion Prophenophos 
 
 
87 
 
 
9.2.5 CORRELATION OF CLINICAL OUTCOMES WITH GASTRIC 
LAVAGE 
 
9.2.5.1 CLINICAL COURSE OF PATIENTS IN THE HOSPITAL WITH 
PRIOR GASTRIC LAVAGE VERSUS THOSE WITHOUT 
GASTRIC LAVAGE 
         There was no difference in the severity of poisoning, ICU admission, need for 
mechanical ventilation, development of intermediate syndrome or death between patients 
with prior gastric lavage before coming to CMC  compared to those who did not have a 
prior gastric lavage. There was no clinical benefit from prior gastric lavage before 
admission. (Table 23) 
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Table 23: Clinical correlation of outcomes in those who had a prior gastric lavage 
versus those who have not had a prior gastric lavage 
Clinical course in the 
hospital 
Prior GL 
n = 27 
No prior GL 
n = 15 
p value 
Severity of poisoning 
Latent 
Mild 
Moderate 
Severe 
 
3 (11.1%) 
8 (29.6%) 
2 (7.4%) 
14 (51.9%) 
 
3 (20%) 
6 (40%) 
2 (13.3%) 
4 (26.7%) 
0.597 
ICU admission 
Yes 
No 
 
14 (51.9%) 
13 (48.1%) 
 
6 (40%) 
9 (60%) 
0.461 
Mechanical ventilation 
Yes 
No 
 
14 (51.9%) 
13 (48.1%) 
 
6 (40%) 
9 (60%) 
0.461 
Intermediate syndrome 
Yes 
No 
 
3 (11.1%) 
24 (88.9%) 
 
4 (26.7%) 
11 (73.3%) 
0.225 
Final outcome 
Death 
Discharge 
DAMA 
 
2 (7.4%) 
24 (88.9%) 
1 (3.7%) 
 
0 
13 (86.7%) 
2 (13.3%) 
0.361 
 
9.2.5.2 CLINICAL OUTCOMES IN THOSE WITH DETECTABLE OP IN 
THE STOMACH 
         The presence or absence of OP in the stomach  did not have an effect on the clinical 
course of the patient in the hospital. There was no significant difference in the severity, 
ICU admission, mechanical ventilation rates or deaths between those who had  detectable 
OP versus those who did not. 
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Table 24: Clinical correlation with presence of OP in the first gastric aspirate 
 OP DETECTED IN 
STOMACH (23) 
N(%) 
 
OP NOT DETECTED 
IN STOMACH(11) 
N(%) 
P 
value 
Severity of poisoning 
Latent 
Mild 
Moderate 
Severe 
 
3(13.0%) 
8(34.8%) 
3(13.0%) 
9(39.1%) 
 
2 (18.2%) 
3 (27.3%) 
1 (9.1%) 
5 (45.5%) 
1.000 
ICU admission 
Yes 
No 
 
12 (52.2%) 
11(47.8%) 
 
5(45.5%) 
6 (54.5%) 
1.000 
Mechanical 
ventilation 
Yes 
No 
 
11 (47.8%) 
12 (52.2%) 
 
6 (54.5%) 
5 (45.5%) 
1.000 
Intermediate 
syndrome 
Yes 
No 
 
4(17.4%) 
19 (82.6%) 
 
2 (18.2%) 
9 (81.8%) 
1.000 
Final outcome 
Death 
Discharge 
DAMA 
 
1 (4.3%) 
20 (87.0%) 
2(8.7%) 
 
2(18.2%) 
9 (81.8%) 
0 
0.319 
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9.2.5.3 CLINICAL COURSE OF PATIENTS WITH DETECTABLE OP IN 
STOMACH AFTER 3 CYCLES OF GASTRIC LAVAGE 
         Majority of the patients had detectable OP in the stomach even after 3 cycles of 
gastric lavage (52.2%). 
Group 1: Patients with detectable OP in the stomach after 3 cycles of gastric lavage 
Group 2: Patients with no detectable OP in the stomach after 3 cycles of gastric lavage 
         Out of the 12 patients with detectable OP in the stomach after 3 cycles of GL, 
50.0% had a severe presentation (Namba scale) and 58.3% required ICU admission. 
However, all 12 were discharged alive from the hospital. There was no statistically 
significant difference in the severity of poisoning, ICU admission, mechanical 
ventilation, intermediate syndrome or death in patients with or without detectable OP in 
the stomach at the end of 3 cycles of gastric lavage.(Table 25) 
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Table 25: Comparison of the clinical course in patients with detectable OP and no 
detectable OP in the stomach at the end of 3 cycles of GL (Group1 –Detectable OP 
at the end of Cycle 3, Group 2- No detectable OP at the end of the cycle 3) 
Clinical course in the 
hospital 
Group 1 
n = 12 
Group 2 
n = 11 
p value 
Severity of poisoning 
Latent 
Mild 
Moderate 
Severe 
 
1(8.3%) 
4(33.3%) 
1(8.3%) 
6(50.0%) 
 
2(18.2%) 
3(27.3%) 
2(18.2%) 
4(36.4%) 
0.824 
ICU admission 
Yes 
No 
 
7(58.3%) 
5(41.7%) 
 
6(54.5%) 
5(45.5%) 
1.000 
Mechanical ventilation 
Yes 
No 
 
 
7(58.3%) 
5(41.7%) 
 
 
6(54.5%) 
5(45.5%) 
1.000 
Intermediate syndrome 
Yes 
No 
 
3(25.0%) 
9(75.0%) 
 
1(9.1%) 
10(90.9%) 
0.590 
Final outcome 
Death 
Discharge 
DAMA 
 
0 
12(100%) 
0 
 
1 (9.1%) 
8(72.7%) 
2(18.2%) 
0.093 
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10 DISCUSSION 
While gastric lavage is widely used in management of OP poisoning patients in India, 
there has been the lack of evidence from randomised controlled trials regarding its 
potential benefit. The current study was not conducted as a treatment trial. It was 
designed as a mechanistic study, to explore the mechanism of gastric lavage and its 
potential therapeutic benefit. If gastric lavage was effective it was hypothesised that: 
(1) OP will be present in the stomach 
(2) Significant amount of OP will be removed from the stomach by gastric lavage 
(3) OP will disappear from the stomach at the end of gastric lavage 
. The main study questions were : (1) What is the proportion of patients with detectable 
OP compound in the stomach and the determinants of the presence of OP in the stomach; 
(2) What is the amount of OP removed from the stomach by gastric lavage, (3) What is 
relationship of the OP compound removed with the cycles of gastric lavage, (4) How 
many cycles of gastric lavage are required to remove OP from stomach. This analysis 
may provide some understanding of the potential benefit from this procedure. 
10.1 PATIENT PROFILE 
The study excluded patients who came after 6 hours as most guidelines advocate gastric 
lavage in patients who reach the hospital within 1 hour of consumption of the compound. 
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The majority of the patients were young working men and women. Most of them were 
farmers and labourers with easy access to insecticide compounds.  Most of the patients 
had ingested diethyl OP compounds (45.5%), 50% were WHO Class I OP compounds 
and 82% were fat soluble OP compounds. More than 50% of patients had moderate to 
severe poisoning. 47.6% of patients required ICU admission and mechanical ventilation, 
16.7% developed intermediate syndrome and 4.8% of patient died. The spectrum of OP 
poisoning were seriously poisoned patients admitted to a tertiary referral hospital. The 
spectrum is similar to other reported studies on OP poisoning from our institution. 
(101)Despite restriction on Class I OP compounds in India, they are still the most 
common OP compound ingested in deliberate self harm. 
People came early to a hospital (mean time to presentation to any medical centre was 
1.35 hours and to our hospital 2.9 hours). The results show that patients are being 
transported quickly to the hospital probably because of the availability of ambulance 
services such as the 108. 71% had had prior decontamination procedures of which 64% 
had gastric lavage before coming to the hospital. The results show that in Tamil Nadu 
gastric lavage is widely used at the first point of care. 
10.2 GASTRIC LAVAGE AND OP POISONING 
10.2.1 Procedure 
In this study it was shown that when gastric lavage can be done safely and effectively by 
a trained person with low complication rates. In all the study patients the targets of the 
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procedure (continuing gastric lavage till there was no OP smell and the aspirate was 
clear) were fulfilled. The amount of fluid that was instilled was almost equal to that 
aspirated, further confirming that the procedure was done properly. Three cycles of 
gastric lavage was required to achieve the above targets. 
Study question (1) What is the proportion of patients with detectable OP compound in the 
stomach and the determinants of the presence of OP in the stomach? 
In this study 70.5% of patients who underwent gastric lavage had detectable OP 
compound in the stomach. All the OP compounds identified in the gastric lavage were fat 
soluble compounds. No water soluble OP compounds like monocrotophos or 
dimethoate could be identified in the gastric sample. This finding could be because 
water soluble OP compound were rapidly absorbed by the gastric mucosa or were rapidly 
transported into the small intestine by gastric peristalsis. No other factors like amount of 
OP consumed, lag time or prior gastric decontamination showed relation to presence of 
OP in the stomach. Even people who had prior gastric lavage elsewhere had detectable 
OP in the stomach at presentation which probably suggests that prior gastric lavage was 
not adequately done to remove the OP from the stomach. It is important to note that 
proper technique of gastric lavage is necessary to remove OP from the stomach.  The 
amount of OP in the stomach in the few patients presenting 5-6 hours after poisoning was 
lower than those presenting earlier. Therefore there appeared to be trend of decline of the 
amount of OP in the stomach with time.  
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Study question (2) What is the amount of OP removed from the stomach by gastric 
lavage? 
The average amount of OP removed by gastric lavage was about 4 mg in patients with 
initial gastric aspirate and 2.6 mg in patients without gastric aspirate. 
Study question (3) What is relationship of the OP compound removed with the cycles of 
gastric lavage? 
90% of OP was removed from the stomach with the first gastric aspirate or the first 
cycle of gastric lavage. There was a declining trend in the amount of OP in the stomach 
with subsequent cycles. This similar finding was demonstrated individually for patients 
who had ingested four fat soluble OP compounds, chlorpyrifos, Triazhophos, 
Propenophos and Methylparathion. 
Study question (4) How many cycles of gastric lavage are required to remove OP from 
stomach? 
The proportion of patients who did not have OP in the stomach increased with each cycle. 
However even after 3 cycles of gastric lavage, 50% had detectable OP in the stomach 
although the levels may be significantly low. The presence of OP in the in the stomach 
after 3 cycles of lavage did not bear any relationship the clinical course of the patients. 
Therefore, it is not clear if the presence of low concentrations of OP in the stomach at the 
end of the gastric lavage is clinically significant. 
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Overall question:  Do the results suggest that gastric lavage may have potential 
therapeutic efficacy? 
Since gastric lavage is a decontamination procedure, to be effective a significant 
proportion of the amount ingested should be removed. In this study we show that the 
amount of OP compound removed by gastric lavage is in few mg range while the amount 
of OP compound ingested is usually in many grams range. It is estimated that less than 
1% of OP ingested is removed by gastric lavage. Clearly gastric lavage removes OP 
compound that is present in the stomach. However the actual amount removed is small in 
relation to that which is ingested. This lack of removal of significant OP by gastric 
decontamination is probably because OP has already been rapidly absorbed from the 
stomach or has rapidly transited into the intestine. 
Despite the proper performance of gastric lavage decontamination procedure in this 
study, significant proportion of patients required ICU care, mechanical ventilation and 
developed intermediate syndrome and a few patients died. All these are consistent with 
the gastric lavage data that the majority of OP is absorbed despite gastric lavage and 
caused significant toxicity. From this data it is unlikely that gastric lavage will result in 
clinically significant benefit. 
The study only included patients who had gastric lavage, and there was no comparison 
arm to examine clinical outcomes. However we analysed different gastric lavage 
variables and clinical outcomes. Neither prior gastric lavage, the absence of OP in the 
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stomach at presentation, nor the disappearance of OP from the stomach at the end of the 3 
cycles had any relation to clinical outcome. 
Overall the study showed that only a small amount of OP is removed by gastric lavage in 
relation to the amount ingested. The small amount of OP removed and the development 
of complications of OP poisoning such as respiratory failure and intermediate syndrome 
despite gastric lavage, suggest that the overall efficacy of gastric lavage is likely to 
small. 
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11 IMPLICATIONS OF THE STUDY 
Though gastric lavage is the standard of care in developing countries like India, there are 
no studies favouring its benefit of this procedure. This study shows that gastric lavage is a 
safe, simple, easy and cost effective procedure of decreasing the OP from the stomach. 
The study of the mechanism of gastric lavage suggests though the gastric lavage can 
remove measurable amount of OP from the stomach, the potential clinical benefit of this 
therapeutic procedure is likely to be low. The first aspirate or the first cycle gastric of the 
gastric lavage is the most beneficial, and therefore this study raises the question regarding 
the need for multiple cycles of lavage. 
 
12 DIRECTIONS FOR FURTHER WORK 
Further studies that need to be done are: 
1. OP levels in serum before and after lavage 
2. Single versus multiple cycles of gastric lavage 
3. Role of prehospital decontamination procedures 
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13 LIMITATIONS 
1. The sample size was small as this was a pilot study and the HPLC analysis was also 
done on a small sample. 
2. The lack of standards because of which 8 gastric samples could not be analysed 
3. HPLC measurement of OP compounds in the patient‘s blood could not be done to 
support the clinical and laboratory studies. 
4. The accuracy of historical data especially with regard to the amount of OP consumed. 
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14 CONCLUSION 
Organophosphorus poisoning is still a major problem in South India and is a cause of 
morbidity and mortality. Gastric lavage is a standard of care and is a commonly done 
procedure in developing countries. However the efficacy of this procedure is not clear. 
This study detected OP compounds in the gastric lavage in 70.6% patients. Lipid soluble 
compounds were detected in the gastric aspirate but none of the water soluble OP 
compounds could be detected in the stomach. Apart from lipid solubility, no other factors 
determined the presence of OP in stomach. An average of 4mg of OP was removed by 
gastric lavage in those with a gastric aspirate. Gastric lavage did remove OP from the 
stomach with the maximum (79.38%) being removed by the first gastric aspirate or the 
first cycle of the gastric lavage. However, it is estimated that <1% of the total OP 
ingested was removed by gastric lavage. More than 50% of patients had detectable OP at 
the end of gastric lavage although at very low concentrations. There were no significant 
differences in the clinical outcome with respect to prior lavage, presence of OP in first 
gastric aspirate or detectable OP at the end of 3 cycles gastric lavage. 
Thus, it can be concluded that gastric lavage does remove measurable OP from the 
stomach. It is a safe, easy and cost effective procedure. The amount of OP removed from 
the stomach is very small when compared to the amount ingested. The study of the 
mechanism of gastric lavage suggests though the gastric lavage can remove measurable 
amount of OP from the stomach, the potential clinical benefit of this therapeutic 
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procedure is likely to be low. Further studies are required to assess the benefit of gastric 
lavage in OP poisoning.  
We would recommend gastric lavage although its potential benefit appears to be low. 
Nursing and the emergency medical staff should be trained in the correct procedure of 
gastric lavage to avoid complications. Gastric lavage should be done as early as possible 
and definitely within the first six hours. 
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16 ANNEXURES 
16.1 ANNEXURE 1 – PATIENT INFORMATION SHEET 
 
You are being requested to participate in a study involving  patients with consumption of 
organophosphate(insecticide). Please read this information form carefully. Take time to 
ask as many questions as you want. The study personnel will explain any word or 
information you do not clearly understand. 
DESCRIPTION OF THE STUDY 
Self poisoning is the most common form of deliberate self harm and pesticides are now 
the most common method of suicide worldwide. Organophosphates are pesticides which 
are easily available and commonly used. The treatment of patients with organophosphate 
poisoning  includes gastric decontamination procedures like gastric lavge, the efficacy 
and use of which has not been well studied.  As per casualty protocol all patients with 
organophosphate consumption within 6 hours undergo gastric lavage. The possible risks 
of the procedure are aspiration, arrhythmias, and in rare conditions cardiac arrest. The 
purpose of this study is to know the amount of organophosphate removed  by gastric 
decontamination. Patients will be enrolled over a period of 2 years for this study. 
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FORESEEABLE RISKS OR INCONVENIENCES 
Gastric lavage is a procedure that is commonly done for acute poisonings. There are no 
inconveniences expected to you by participating in this study. Nasogastric tube will be 
inserted and all stomach contents will be aspirated following which cycles of gastric 
lavage will be done and samples will be collected from each aspirate and amount of 
organophosphate will be calculated in the lavage fluid. The investigation will be done 
free of cost for you; you will not be required to pay any money at any stage for the study 
purpose. 
REASONABLY EXPECTED BENEFITS 
You will not be given any financial or in kind rewards for participating in this study but 
the data obtained may be useful for patients in the future. 
STUDY PARTICIPATION AND WITHDRAWAL 
Your participation in this study is strictly voluntary. You have the right to leave this study 
at any time. Refusal to participate or study discontinuation will not result in any penalty, 
or compromise of your medical care, or loss of benefits. 
DATA COLLECTED 
If you consent to participate in this study, the study personnel will collect the following 
information  
 
 
 
111 
 
about you: demographic data, time of consumption, name and volume  of compound 
consumed , prior gastric lavage, induced vomiting,examination findings and  results of 
your blood/gastric aspirate tests and details of your treatment while in the hospital. 
CONFIDENTIALITY OF YOUR INFORMATION 
Your personal data will remain strictly confidential. Only the study doctors will be able 
to match your data to your identity. If the results of this study are published, you will not 
be identified by name in any publication or presentation of results. 
The procedures of the study not painful and do not cause any threat to health. Please 
contact me if you have any doubts. (Dr._____________, Phone No.______________) 
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16.2 ANNEXURE 2 – INFORMED CONSENT FORM 
 
    Hospital 
Number 
       Study ID        Participant’s Name Age 
    
 
i) I confirm that I have read and understood the information sheet dated 
____________ for   the above study and have had the opportunity to ask 
questions. [ ] 
 
      (ii)     I understand that my participation in the study is voluntary and that I am free to   
               withdraw at any  time, without giving any reason, without my medical care or  
               legal rights being affected. [ ] 
     (iii ) I understand that the Sponsor of the clinical trial, others working on the  
             Sponsor’s behalf, the Ethics Committee and the regulatory authorities will not  
             need my permission to look at my health records both in respect of the current  
             study and any further research that may be conducted in relation to it, even if I  
             withdraw from the trial. I agree to this access. However, I understand that my  
             identity will not be revealed in any information released to third parties   or    
            published. [ ] 
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    (iv) I agree not to restrict the use of any data or results that arise from this study   
         provided such use is only for scientific purpose(s). [ ] 
  (v)  I agree to take part in the above study. [ ] 
 
    Name of the study participant / signatory:  
     
   Signature / Thumb impression:                                                                         
Investigator’s signature: 
 
 
 
 
Date:_____/_____/_____                                               Date:_____/_____/______ 
                                                            
Name of witness: _________________________________________ 
Witness signature: 
 
 
Date: _____/_____/______ 
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16.3 ANNEXURE 3 – PATIENT PROFORMA 
 
                                                        CLINICAL RESEARCH FORM 
ACUTE ORGANOPHOSPHATE POISONINGS 
DEMOGRAPHIC DATA 
Name:                                                                    Age:                                    Sex: 
 
Hospital number: 
 
Address   :  
 
------------------------------------------------------------------------------------------------------------
- 
Method of case ascertainment: 
Tick as appropriate 
1) History of organophosphorous poisoning with an identified compound based on 
 Based on oral  self-report  
 Bringing the pesticide container  
 Pamphlet of the consumed pesticide. 
2) Cholinergic crises 
3) Low butrylcholinesterase 
      
   M/F  
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POISONING DATA 
Date of ingestion                         :                        
Time of ingestion                        : 
Date of presentation to CMC      :                        
Time of presentation to CMC     : 
Name of OP compound               : 
Class of OP compound                : 
Estimated Amount ingested         :               
 
TREATMENT BEFORE ADMISSION any pertinent details 
 
Forced emesis                Method: 
Gastric lavage                           
Activated charcoal 
Atropine        
PAM 
No treatment 
Treatment given at – CMC peripheral units / government district hospital / NGO / 
Government medical college / Private hospital 
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HOSPITAL TREATMENT DATA 
BP       :               PULSE:                 RR:                       SPO2:            IF OXYGEN, 
FLOW RATE 
GCS    :  E             V           M             TOTAL  
GRBS:  
 
SYMPTOMS AT PRESENTATION: 
Vomiting/ diarrhea/ abdominal pain/ salivation/ sweating/ blurring of vision/ urinary 
incontinence/ drowsiness/ breathing difficulty/ seizures/ altered sensorium 
Other symptoms: ……………………………… 
 
SIGNS AT PRESENTATION: 
Diaphoresis                            Y/N 
Pupil size                                Y/N 
Lung crepitations                   Y/N 
Salivation/frothing                 Y/N 
Fasciculations                        Y/N 
Muscle weakness (Power) 
Upper limb shoulder grade     : 
Lower limb hip grade             :  
Single breath count                :     
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Paradoxical breathing            Y/N 
Abdominal tenderness           Y/N 
Fever                                      Y/N 
Other signs :   …………………………   
     
INVESTIGATIONS: 
S.Pseudocholinesterase               : 
Serum level of OP compound     : 
Name of OP compound               : 
Severity of poisoning 
The severity of OP poisoning will be assessed using the namba scale* 
Latent 
Mild 
Moderate 
Severe 
GASTRIC LAVAGE    
Time of gastric lavage: 
Performed by: 
 Volume aspirated Colour and smell 
Cycle 1   
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Cycle 2   
Cycle 3   
Cycle 4   
Total volume   
 
 
Serum level of OP post gastric lavage :    
COMPLICATIONS OF GASTRIC LAVAGE 
Laryngospasms (decrease in sp 02, bradycardia, breathing difficulty, hemodynamic 
instability) 
Aspiration pneumonia 
Arrhythmias 
Esophageal/ gastric perforation 
Cardiac arrest 
 
TREATMENT DETAILS 
Antidote administered                         yes/no 
ICU admission                                     yes/no 
Days of ICU stay               
Mechanical Ventilation                        yes/no 
Duration of mechanical ventilation     
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 Day 
1 
Day 
2 
Day 
3 
Day 4 Day 5 Day 6 Day 7 Day 8 Day 9 
GCS          
Cholinergic 
crises 
         
Muscle 
weakness 
Upper limb 
 lower limb 
         
Mechanical 
ventilation 
present/absent 
         
Total daily 
atropine dose 
         
Any other 
complication 
         
 
 
COMPLICATIONS DURING HOSPITAL STAY  
Cholinergic crises(y/n): 
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Duration of cholinergic crises: 
Coma(y/n): 
Duration of coma: 
Intermediate syndrome(y/n): 
Duration of IMS: 
Mechanical ventilation(y/n): 
Duration of mechanical ventilation: 
Aspiration pneumonia(y/n):  
Nosocomial pneumonia(y/n): 
Cardiac arrest/Respiratory arrest(y/n): 
OUTCOME DATA 
OP Poisoning         : accidental / deliberate self harm 
Outcome                : dead / alive / DAMA 
Date of discharge/death/DAMA        
Time of discharge/death/DAMA 
 
Cause of death   
 
Duration of ICU care 
Duration of hospitalization 
Summary clinical data: 
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1. Lag time from OP ingestion to gastric lavage:  hours 
2. Pre-lavage decontamination procedure:  Present/Absent 
a. Vomiting 
b. Induced emesis 
c. Activated Charcoal 
d. Gastric lavage 
3. Volume of compound ingested:   ml 
4. Severity of poisoning: Latent/Mild/Moderate/Severe 
5. Low GCS 
6. Weakness at admission  
7. Cholinergic crises: Present/Absent           
Duration: 
8. Intermediate syndrome: Present/Absent  
Duration: 
9. Coma: Present/Absent                 
Duration: 
10. Nosocomial pneumonia: Present/Absent 
11. Treatment 
a) Activated Charcoal: Present/Absent  
 Number of doses: 
b) ICU care present/absent  
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 Duration: 
c) Atropine: present/absent  
 Number of days:  
d) Total atropine dose: 
e) Mechanical ventilation: Present/Absent  
 Duration 
f) Tracheostomy: Present/Absent 
g) Antibiotics Present/Absent 
12. Complications of gastric lavage 
a) Laryngospasms (decrease in sp 02, bradycardia, breathing difficulty, 
hemodynamic instability) 
b) Aspiration pneumonia 
c) Arrhythmias 
d) Esophageal/ gastric perforation 
e) Cardiac arrest 
      13.  Final Outcome: discharge / death / DAMA  
Laboratory data 
OP compound: 
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 Bottle A Bottle B Bottle C Bottle D 
GL aspirate volume     
OP concentration     
Amount of OP     
 
Pre Gastric lavage OP concentration: 
OP concentration in last gastric lavage aspirated 
Total amount of OP aspirated: 
Pre-lavage serum concentration of OP: 
Post-lavage serum concentration of OP: 
*The severity of OP poisoning will be assessed using the namba scale 
 Namba grade                                                              Clinical presentation 
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Namba 1 or Latent 
No clinical manifestations 
Severity assessed by measurement of 
serum cholinesterase levels which is 
inhibited by 10-50 % 
Namba II or mild 
The patient can walk but complains of 
dizziness, headache, numbness of 
extremities, nausea and vomiting, 
excessive sweating and salivation, 
tightness in chest, abdominal cramps or 
diarrhoea. 
Serum cholinesterase level is 20-505 of 
normal. 
Namba III or Moderate                                     
The patient cannot walk and there is 
generalized weakness, difficulty talking, 
muscular fasciculation, miosis. 
Cholinesterase level is 10-20% of normal 
Namba IV or Severe                                          
Unconsciousness, marked miosis and loss 
of pupil reflex to light, muscular 
fasciculation, flaccid paralysis, secretions 
from the mouth and nose, moist rales in 
the lungs, respiratory difficulty and 
cyanosis. 
Serum Cholinesterase levels are less than 
10% of normal. 
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16.4 ANNEXURE 4 – DATA AND SAMPLE COLLECTION PROTOCOL 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
All patients who come to casualty with 
acute organophosphate poisoning 
 
NG inserted and contents aspirated. 
Sample collected in a bottle ‘A’ with 
the total volume of aspirate labeled 
over it 
 
Informed consent 
 
Demographic, clinical and lab 
(including blood level of OP) 
details entered in data sheet 
 
Gastric lavage performed and 10ml 
sample from each cycle of gastric lavage 
fluid collected in bottles labeled B, C, 
and D with total volume of each GL 
aspirate labeled over each bottle 
 
Samples sent to clinical biochemistry lab 
for HPLC testing to assess concentration 
of OP in each sample 
 
Inclusion and exclusion 
criteria  
 
Concentration of OP before and after 
lavage compared 
 
Blood sample 
taken to test OP 
level  
Clinical 
follow-up 
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16.5 ANNEXURE 5 : DATA SHEET 
 
 slno  age  sex  address  organophos  oral  pestcont  pamphlet  cholicrise  butryl  doi  toi  dofhc  tofhc FHC 1  dopcmc  topcmc FHC2  nameop  oppercent WHO
1 23 Male Yes Yes No No Yes Yes 4/23/2015 13.2 4/23/2015 14.4 1.5 4/23/2015 14.4 1.5 unknown
2 54 Male No No No No Yes No 4/29/2015 16.3 4/29/2015 18 1.5 4/29/2015 21 4.5 unknown
3 19 Female Yes No Yes No No Yes 5/14/2015 20 5/14/2015 21.15 1 5/14/2015 21.15 1 dichlorvas 76 1
4 34 Male Yes No Yes No Yes No 5/22/2015 19.45 5/22/2015 20.4 1 5/22/2015 20.4 1 Quinalphos 25 2
5 24 Female Yes No Yes No Yes No 6/12/2015 17 6/12/2015 18 1 6/12/2015 20.5 4 dimethoate 35 2
6 24 Female Yes No No Yes No No 5/22/2015 18.39 5/22/2015 21.15 3 5/22/2015 21.15 3 methylparathion 2 1
7 20 Female Yes No Yes No No No 5/28/2015 20 5/28/2015 21.5 2 5/28/2015 21.5 2 profenophos + cypermethrin 40 3
8 26 Male Yes No Yes No No No 5/28/2015 20 5/28/2015 21.5 2 5/28/2015 21.5 2 profenophos + cypermethrin 40 3
9 17 Female Yes No Yes No No No 6/11/2015 7 6/11/2015 8 1 6/11/2015 12.2 5.5 monocrotophos 36 1
10 19 Male Yes No No Yes No No 6/14/2015 11.3 6/14/2015 12 0.5 6/14/2015 17.2 6 dimethoate 30 2
11 19 Male Yes No Yes No Yes Yes 6/25/2015 10 6/25/2015 15 5 6/25/2015 16 6 dimethoate 30 2
12 55 Male Yes No No Yes Yes No 6/30/2015 14 6/30/2015 15 1 6/30/2015 15.3 1.5 triazophos + deltamethrin 35 1
13 23 Male Yes No Yes No No No 7/25/2015 18.3 7/25/2015 19.3 1 7/25/2015 23 4.5 phorate 10 1
14 64 Female Yes Yes No No Yes No 8/3/2015 12 8/3/2015 13.3 1.5 8/3/2015 14.45 2.5 unknown
15 33 Female Yes No Yes No Yes No 8/14/2015 8 8/14/2015 9.3 1.5 8/14/2015 9.3 1.5 malathion 5 3
16 25 Male Yes Yes No No Yes Yes 11/18/2015 13 11/18/2015 13.3 0.5 11/18/2015 14.15 1 unknown
17 49 Male Yes No Yes No No No 3/14/2016 16 3/14/2016 20 4 3/14/2016 20 4 unknown
18 70 Female Yes Yes No No Yes No 6/13/2015 19 6/13/2015 19.3 0.5 6/13/2015 20.45 2 unknown
19 28 Male Yes No No Yes No No 7/29/2015 14.3 7/29/2015 17.3 3 7/29/2015 17.3 3 monocrotophos 30 1
20 26 Male Yes Yes No No Yes No 6/30/2015 14 6/30/2016 15 1 6/30/2016 16.15 2 unknown
21 20 Male Yes No Yes No Yes Yes 8/23/2015 19.3 8/23/2015 20 0.5 8/23/2015 21 1.5 chlorpyriphos + deltamethrin 20 2
22 25 Male Yes Yes Yes No Yes Yes 8/2/2015 11 8/2/2015 12 1 8/2/2015 12 1 Profenophos 50 3
23 27 Male T.V.Malai, Tamil naduYes No Yes No Yes Yes 9/18/2015 13.3 9/18/2015 16 2.5 9/18/2015 16 2.5 triazophos 40 1
24 35 Female Yes Yes No No Yes No 2/9/2016 17 2/9/2016 19 2 2/9/2016 20.15 3 unknown
25 34 Male Yes No Yes No Yes Yes 12/4/2015 15.3 12/4/2015 16 0.5 12/4/2015 18 2.5 triazophos + deltamethrin 39 1
26 20 Male vellore Yes No Yes No No No 1/25/2016 9.3 1/25/2016 10.3 1.0 1/25/2016 11 1.5 monocrotophos 36 1
27 25 Female Yes No Yes No No No 2/16/2016 12.3 2/16/2016 13 0.50 2/16/2016 16.3 4 chlorpyriphos 20 2
28 25 Female Yes No Yes No Yes Yes 2/17/2016 9.3 2/17/2016 10.3 1 2/17/2016 12.3 3 chlorpyriphos 20 2
29 38 Male Yes No Yes No Yes Yes 2/17/2016 9 2/17/2016 10 1 2/17/2016 13 4 ethion + cypermethrin 40 3
30 30 Female Yes No No Yes Yes No 2/19/2016 17 2/19/2016 17.3 0.5 2/19/2016 19.45 3 triazophos 35 1
31 53 Female Yes No Yes No Yes Yes 2/21/2016 9.5 2/21/2016 10.3 0.5 2/21/2016 13.3 3.5 dichlorvas 76 1
32 15 Female Yes No Yes No Yes Yes 2/23/2316 11 2/23/2316 12 1 2/23/2316 15.25 4.5 phorate 10 1
33 30 Female Yes No Yes No No Yes 2/24/2016 12.3 2/24/2016 14.3 2.00   2/24/2016 17.3 5 phorate 10 1
34 26 Male Yes Yes No No Yes Yes 2/29/2016 14 2/29/2016 15 1 2/29/2016 16 2 unknown
35 31 Male Yes No No Yes No No 2/28/2016 15 2/28/2016 16 1 2/28/2016 18.3 3.5 phorate 10 1
36 28 Female Yes No No Yes No Yes 3/14/2016 19 3/14/2016 20 1 3/14/2016 20.3 1.5 triazophos + deltamethrin 35 1
37 23 Male Yes No Yes No Yes 4/4/2016 1.15 4/4/2016 2 0.5 4/4/2016 6 5 Triazophos 40 1
38 19 Female Yes No Yes No No No 4/10/2016 11 4/10/2016 11.3 0.5 4/10/2016 13 2 profenophos + cypermethrin 40 3
39 27 Female Yes No Yes No No No 4/23/2016 8.3 4/23/2016 9 0.5 4/23/2016 10.3 2 penthoate 2
40 29 Female Yes No Yes No No Yes 5/7/2016 8 5/7/2016 8.45 1 5/7/2016 11 3 chlorpyriphos 20 2
41 41 Female Yes No Yes No No Yes 5/13/2016 3.45 5/13/2016 4.15 0.5 5/13/2016 5.3 2 chlorpyriphos + cyhalothrin + cypermethrin40 2
42 30 Male Yes Yes No No No Yes 5/26/2016 6 5/26/2016 9.3 3.5 5/26/2016 9.3 3.5 dichlorvas 1
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 classop  pyrethroid  pyifyres  eai TAI  forced  method  gastric charcoal  atropine  pam  notreat  treatgiven  sysbp  diasbp  pulse  rr  spo2  oxygen  flowchart  e  v  m  gcstotal  grbs  vomiting 
300 No No No No No Yes 110 70 72 20 99 No 4 5 6 15 82 Yes
60 Yes No No Yes Yes No Government medical college 140 80 72 20 96 Yes 10 3 2 5 10 93 Yes
dimethyl No 20 No No No No No Yes 120 80 102 20 99 No 4 5 6 15 204 Yes
diethyl No 60 No No No No No Yes 100 60 109 34 80 Yes 10 1 1 1 3 150 Yes
dimethyl No 75 Yes Yes No Yes No No Government distric hospital 100 60 125 8 80 Yes 10 2 2 3 7 151 Yes
dimethyl No 100 Yes No No No No Yes 110 60 60 20 90 No 4 5 6 15 162 Yes
salkyl Yes 4 20 No No No No No Yes 120 80 84 24 97 No 4 5 6 15 130 Yes
salkyl Yes 4 50 20 No No No No No Yes 120 80 84 24 99 No 4 5 6 15 130 Yes
dimethyl No 20 Yes Yes Yes Yes No No Government distric hospital 110 80 102 44 80 Yes 10 1 1 1 3 284 Yes
dimethyl No 100 No Yes No Yes No No Government distric hospital 120 70 126 16 97 No 4 4 6 14 120 Yes
dimethyl No 75 No Yes No No No Yes Government distric hospital 90 60 152 40 70 Yes 10 1 1 1 3 193 Yes
diethyl Yes 1 25 No Yes No No No No Government distric hospital 120 70 130 22 88 Yes 6 4 5 6 15 177 Yes
diethyl No 50 No Yes No No No No Government distric hospital 110 70 104 24 98 No 4 5 6 15 92 Yes
50 No Yes No Yes No No Government distric hospital 90 60 103 22 97 No 3 5 6 14 120 Yes
dimethyl No 100 No No No No No Yes 100 70 75 24 96 No 4 5 6 15 94 Yes
50 No Yes No No No No Government distric hospital 130 80 96 40 80 Yes 10 3 0 5 8 140 Yes
No No No No No Yes 100 80 110 24 99 No 10 4 5 6 15 210 Yes
50 No Yes No No No No Government distric hospital 140 80 102 16 99 No 4 5 6 15 140 Yes
dimethyl No 10 No No No No No Yes 110 70 90 20 99 No 4 5 6 15 130 No
50 No Yes No No No No Government distric hospital 90 0 80 40 80 Yes 10 1 1 1 3 200 Yes
dimethyl Yes 50 10 No Yes No Yes Yes No Government distric hospital 120 70 70 20 99 No 4 5 6 15 120 Yes
salkyl No 30 15 No No No No No Yes Government distric hospital 130 80 86 22 98 No 4 5 6 15 130 Yes
diethyl No 100 15 No No No No No Yes 90 60 110 26 90 Yes 10 2 2 4 8 101 Yes
No Yes No Yes No No Government distric hospital 120 80 110 30 78 Yes 10 4 4 5 13 160 Yes
diethyl Yes 1 100 39 No Yes No No No No Government distric hospital 90 60 110 36 99 Yes 10 3 2 4 9 210 Yes
dimethyl No 50 No Yes No Yes No No Government distric hospital 100 70 110 16 99 No 4 5 6 15 120 No
diethyl No 100 20 Yes No No Yes No No Government distric hospital 120 80 102 24 98 No 4 5 5 14 93 No
diethyl No 40 8 No Yes No Yes No No Government distric hospital 110 80 118 28 99 No 4 5 6 15 82 Yes
others Yes 5 100 No No No Yes No No Government distric hospital 110 80 128 36 92 Yes 10 1 1 1 3 278 No
diethyl No 100 No Yes No Yes No No Government distric hospital 100 70 103 12 94 Yes 10 2 2 4 8 121 Yes
dimethyl No 25 Yes Yes No Yes Yes No Government distric hospital 110 70 126 22 99 Yes 6 3 4 5 12 293 Yes
diethyl No No Yes No Yes No No Government distric hospital 140 80 130 36 86 Yes 10 1 1 1 3 200 Yes
diethyl No 10 No Yes No Yes Yes No Government distric hospital 100 80 148 22 94 Yes 2 4 5 6 15 110 Yes
100 No Yes No Yes No No Government distric hospital 110 70 110 36 96 Yes 6 1 1 1 3 146 Yes
diethyl No No Yes No Yes No No Government distric hospital 140 80 102 24 98 No 4 4 5 13 148 Yes
diethyl Yes 1 100 No Yes No Yes No No Government distric hospital 100 70 114 36 70 Yes 10 1 1 1 3 178 No
diethyl No 100 No Yes No Yes Yes No Government distric hospital 100 70 68 22 86 Yes 10 1 1 1 3 202 Yes
salkyl Yes 4 15 6 No Yes No No No No CMC peripheral units 100 60 134 20 99 No 4 5 6 15 101 Yes
dimethyl No 50 No Yes No Yes No No Government distric hospital 110 70 112 16 99 No 4 5 6 15 184 Yes
diethyl No 5 1 No Yes No Yes No No Government distric hospital 110 70 136 24 99 No 4 5 6 15 150 Yes
diethyl Yes 2.5 10 4 No Yes No Yes No No Government distric hospital 110 70 134 26 99 No 4 5 6 15 140 No
dimethyl No 100 No No No No No Yes 110 80 112 34 99 No 4 5 6 15 124 No
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 diarrhea  bdominal  salivation  sweating  blurring  urinary  drowsiness  breathing  seizures  altered  lacri  othsymp  diaphore  pupilsize  lungcrep  salivatio1  fasci  muscleweak  upperlimb  lowerlimb  breath paradox  abdominal1  fever  othersigns  sp eudo  serumlevel  nameofop  soppoison 
No No Yes No Yes No No No No No Yes Yes No No Yes No 2 5 5 40 No No No 250 Mild
No No Yes No No No Yes Yes No Yes No Yes No Yes Yes No 3 3 3 0 Yes No No 7826 Severe
No Yes Yes Yes No No No Yes No No No Yes No No Yes No 2 5 5 41 No No No 340 Mild
No No Yes No No No Yes Yes No Yes No Yes Yes Yes Yes No 2 2 2 0 Yes No No 9251 Severe
No No Yes Yes No No Yes Yes No Yes No Yes Yes Yes Yes No 2 2 2 0 Yes No No 728 Severe
No No Yes No No No No No No No No No No No Yes No 5 5 5 5 No No No 2525 Moderate
No No No No No No No No No No No No No No No No 5 5 5 22 No No No 4251 Mild
No No Yes No No No No No No No No No Yes No Yes No 5 5 5 24 No No No 4208 Mild
No No Yes No No No Yes Yes No Yes No Yes No Yes Yes No 3 3 3 Yes No No 4562 Severe
No No Yes Yes No No No No No Yes No Yes No No Yes No 5 5 5 15 No No No 1638 Moderate
No No Yes No No No No Yes No Yes No Yes Yes Yes Yes Yes 3 3 3 0 Yes No No 621 Severe
No No Yes Yes No No No No No No No Yes Yes No Yes No 5 5 5 20 No No No 2018 Mild
No No Yes No No No No No No No No No No No Yes No 5 5 5 30 No No No 7326 Mild
No No No No No Yes Yes No No Yes No No No No No No 5 5 5 14 No No No 1752 Mild
No No Yes No No No No No No No No Yes No No Yes No 5 5 5 20 No No No 7101 Mild
Yes No Yes No No Yes Yes Yes No Yes No Yes Yes Yes Yes No 3 3 3 0 Yes No No 110 Severe
No No No No No No No No No No No No No No No No 5 5 5 30 No No No 1165 Latent
No No Yes Yes No No No No No No No Yes No No No No 5 5 5 30 No No No 6947 Mild
No No No No No No No No No No No No No No No No 5 5 5 40 No No No 4540 Latent
Yes No Yes No No No Yes Yes Yes Yes No Yes Yes Yes Yes No 2 2 2 0 Yes No No 2697 Severe
No No Yes Yes No Yes No No No No Yes Yes No No Yes No 5 5 5 30 No No No 371 Mild
No No Yes Yes No No No No No No Yes Yes Yes No Yes No 5 5 5 30 No No No 257 Mild
No No Yes Yes No No Yes No No Yes No Yes Yes No Yes No 3 3 3 No No No 120 Severe
Yes No Yes No No Yes Yes No No Yes Yes No Yes No Yes No 3 3 3 0 No No No 3471 Severe
No No Yes Yes No No Yes No Yes Yes No Yes Yes No Yes No 3 3 3 0 No No No 81 Severe
No No No No No No No No No No No No No No No No 5 5 5 30 No No No 9928 Latent
Yes No Yes No No No Yes No Yes Yes No No No No Yes No 4 4 4 No No No 281 Moderate
No No No No No No No No Yes No No No No No No No 5 5 5 30 No No Yes 71 Moderate
Yes No No No No No Yes Yes No Yes No No Yes Yes No Yes 1 1 1 0 Yes No No 76 Severe
Yes No No No No Yes No No No Yes No No No No Yes No 4 4 4 0 No No No 115 Severe
No No Yes No No No Yes Yes No Yes No No No Yes Yes No 4 4 4 No No Yes 210 Severe
No No Yes No No No Yes Yes Yes Yes No No Yes Yes Yes No 3 3 3 0 No No No 159 Severe
No No No No No No Yes No No No No No No No No No 5 5 5 10 No No No 77 Mild
No No Yes No No No Yes Yes No Yes No No Yes Yes Yes No 3 3 3 0 No No No 91 Severe
Yes No Yes Yes Yes Yes Yes No Yes Yes Yes Yes No Yes Yes Yes 3 3 3 10 Yes No No 150 Severe
No No No No No No No Yes No Yes No No Yes Yes Yes No 1 1 1 0 Yes No No 139 Severe
No No No No No No Yes Yes Yes Yes No No No Yes No No 1 1 1 0 No No No 297 Severe
No No No No No No No No No No No No No No No No 5 5 5 18 No No No 244 Latent
Yes No No No No No No No No No No No No No No No 5 5 5 20 No No No 2995 Mild
No No No No No No No No No No No No No No No No 5 5 5 20 No No No 102 Mild
No No No No No No No No No No No No No No No No 5 5 5 30 No No No 143 Latent
No No No No No No No No No No No No No No No No 5 5 5 30 No No No 161 Latent
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 timegastic  performby  c1vol  c1cs  c2vol  c2cs  c3vol  c3cs  c4vol  c4cs  totalvol  oppostgas  l ryngos  aspipneu  arrhythmia  esophageal  cardiac  antidote 
15 asisha 275 yellow,turbid,OP smell 550 yellow,turbid,OP smell 350 yellow,clear,no smell 750 clear,no smell 1925 No No No No No Yes
21.15 asisha 100 greenish, OP smell 200 green,OP smell 230 light green, no smell 300 clear,no smell 830 No No No No No Yes
21.3 asisha 0 300 yellow,turbid,OP smell 310 yellow,clear,OP smell 395 clear,no OP smell 1005 No No No No No No
20.5 asisha 250 yellow,turbid,OP smell 125 yellow,turbid,OP smell 140 light yellow,no OP smell 235 clear,no smell 750 No No No No No Yes
21 asisha 30 yellow,turbid,OP smell 180 yellow,turbid,OP smell 175 clear,no smell 215 clear,no smell 600 No No No No No Yes
21.3 asisha 50 turbid,op smell 150 clear, no smell 100 clear,no smell 110 clear,no smell 410 No No No No No Yes
22 asisha 0 350 turbid,OP smell 200 turbid,OP smell 400 clear,no smell 950 No No No No No Yes
22 asisha 100 greenish, OP smell 220 greenish, OP smell 230 light green,OP smell 275 clear,no smell 825 No No No No No Yes
8.15 asisha 10 turbid, OP smell 110 turbid,OP smell 215 clear, no OP smell 260 clear,no smell 595 No No No No No Yes
17.2 asisha 5 turbid,OP smell 250 turbid,OP smell 220 clear,no smell 190 clear,no smell 665 No No No No No Yes
16 asisha 180 turbid,OP smell 70 turbid,op smell 120 clear,OP smell 210 clear,No smell 580 No No No No No Yes
15.4 asisha 10 clear,OP smell 75 clear,OP smell 275 clear,no smell 75 clear,no smell 435 No No No No No Yes
23.1 asisha 0 150 no clour,no smell 180 no smell, no colour 250 no smell,no colour 580 No No No No No Yes
14.5 asisha 0 180 turbid,OP smell 200 turbid,OP smell 200 clear,no smell 580 No No No No No Yes
9.45 asisha 10 turbid yellow,OP smell 240 turbid yelllow,OP smell 225 light yellow, OP smell 230 clear,OP smell 705 No No No No No Yes
14.3 asisha 600 turbid,OP smell 150 turbid,OP smell 120 turbid,OP smell 250 clear,OP smell 1120 No No No No No Yes
20.15 asisha 0 300 clear,no smell 210 clear,no smell 150 clear, no smell 660 No No No No No No
21 asisha 33 turbid,OP smell 270 turbid,OP smell 70 clear,no smell 165 clear, no smell 538 No No No No No Yes
17.45 asisha 15 clear, OP smell 100 clear,no smell 110 clear,no smell 140 clear,no smell 365 No No No No No No
16.3 asisha 350 turbid,yellow,OP smell 225 turbid,yellow,OP smell 250 turbid,OP smell 170 clear,OP smell 995 No No No No No Yes
21.15 asisha 30 greenish,OP smell 130 greenish,OP smell 220 light green,OP smell 200 clear,no smell 580 No No No No No Yes
12.15 asisha 100 turbid,OP smell 170 turbid,OP smell 220 clear,no smell 220 clear,no smell 710 No No No No No Yes
16.1 asisha 10 clear, OP smell + 140 clear, OP smell + 170 clear, no OP smell 270 clear, no OP smell 590 No Yes No No No Yes
20.3 asisha 0 200 clear, no OP smell 200 clear,no OP smell 210 clear, no OP smell 610 No No No No No Yes
18.15 asisha 50 turbid, brown ,OP smell + 210 turbid, OP smell + 200 clear, no OP smell 0 460 No No No No No Yes
11.1 asisha 0 170 turbid,OP smell+ 100 turbid, no OP smell 320 clear, no OP smell 590 No No No No No Yes
16.45 asisha 0 200 clear, OP smell + 250 clear,OP smell + 360 clear, No OP smell 810 No No No No No Yes
12.45 asisha 100 dark brown,OP smell+ 120 light brown,OP smell+ 200 light brown,No OP smell 340 clear,No OP smell 760 No No No No No Yes
13.2 asisha 150 turbid,OP smell+ 160 turbid,OP smell+ 220 turbid,OP smell+ 190 turbid,OP smell+ 720 No Yes No No No Yes
20 asisha 20 dark yellow,OP smell+ 190 light yellow,OP smell+ 180 light yellow,OP smell+ 220 clear, no OP smell 610 No No No No No Yes
13.4 asisha 0 200 clear,No OP smell 300 clear, no OP smell 200 clear,no OP smell 700 Yes
3.38 asisha 20 turbid,OP smell+ 100 turbid, OP smell+ 220 clear, no OP smell 310 clear, no OP smell 650 No Yes No No No Yes
17.4 asisha 0 200 clear, OP smell+ 500 clear, no OP smell 190 clear,no OP smell 890 No No No No No Yes
16.15 asisha 10 turbid,yellowish, OP smell+ 200 turbid, yellowish, OP smell+ 210 clear,OP smell+ 220 clear, no OP smell 640 No No No No No Yes
18.45 asisha 0 170 turbid,OP smell+ 190 turbid,OP smell+ 250 clear, no OP smell 610 No No No No No Yes
20.4 aneez 100 turbid,OP smell+ 290 turbid,OP smell+ 400 clear,no OP smell 210 clear,no OP smell 1000 No No No No No Yes
3.3 asisha 0 100 clear,no smell 160 clear,no smell 200 clear,no smell 460 No No No No No Yes
13.15 asisha 0 180 turbid,OP smell+ 240 turbid,OP smell+ 120 turbid,no OP smell 540 No No No No No Yes
10.4 asisha 0 240 turbid, OP smell+ 260 clear, no OP smell 210 clear, no OP smell 710 No No No No No Yes
11.15 asisha 90 yellow,OP smell+ 200 yellow,OP smell+ 210 clear, no OP smell 250 clear, no OP smell 750 No No No No No Yes
5.45 asisha 20 turbid, OP smell + 25 turbid,OP smell + 250 clear,OP smell+ 100 clear, no OP smell 395 No No No No No Yes
9.45 asisha 0 180 yellow,OP smell+ 190 clear, no OP smell 160 clear, no OP smell 530 No No No No No No
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 icuadmis  custay  mechventil  durmv  d1gcs  d1cc  d1ul  d1ll  d1mv  d1atrodose  d1anyoth  d2gcs  d2cc  d2ul  d2ll  d2mv  d2atrodose  d2anyoth  d3gcs  d3cc  d3ul  d3ll  d3mv  d3atrodose  d3anyoth  d4gcs  d4cc  d4ul  d4ll 
No No 15 Yes 5 5 No 35 atropine psychosis15 No 5 5 No 25 15 No 5 5 No 0 15 No 5 5
Yes 3 Yes 2 10 Yes 3 3 Yes 10 10 Yes 3 3 Yes 4 15 No 5 5 No 0
No No 15 Yes 5 5 No 0 15 No 5 5 No 0 15 No 5 5 No 0 15 No 5 5
Yes 9 Yes 7 3 Yes 2 2 Yes 35 3 Yes 2 2 Yes 257 3 No 3 3 Yes 85 7 No 3 3
Yes 6 Yes 6 7 Yes 3 3 Yes 30 10 Yes 3 3 Yes 48 10 Yes 3 3 Yes 36 10 No 4 4
Yes 5 Yes 2 15 Yes 4 4 Yes 22 2 Yes 3 3 Yes 184 9 Yes 4 4 Yes 19 15 No 4 4
No No 15 No 5 5 No 0 15 No 5 5 No 1 15 No 5 5 No 0 15 No 5 5
No No 15 Yes 5 5 No 20 15 No 5 5 No 4 15 No 5 5 No 0 15 No 5 5
Yes 3 Yes 3 3 Yes 2 2 Yes 28 7 Yes 3 3 Yes 23 15 No 4 4 No 0 15 No 5 5
No No 14 Yes 5 5 No 10 15 Yes 5 5 No 20 15 No 5 5 No 24 15 No 5 5
Yes 7 Yes 6 3 Yes 3 3 Yes 327 10 Yes 3 3 Yes 171 10 No 3 3 Yes 74 10 No 4 4
No No 15 Yes 5 5 No 29 15 No 5 5 No 73 15 No 5 5 No 85 15 No 5 5
No No 15 No 5 5 No 0 15 No 5 5 No 2 15 No 5 5 No 2 15 No 5 5
No Yes 0.5 15 Yes 5 5 No 34
No No 15 Yes 5 5 No 13 15 No 5 5 No 8 15 No 5 5 No 0 15 No 5 5
Yes 5 No 4 8 Yes 3 3 Yes 50 8 Yes 3 3 Yes 8 10 No 4 4 Yes 0 10 No 4 4
No No 15 No 5 5 No 0
No No 15 Yes 5 5 No 4
No No 15 No 5 5 No 0 15 No 5 5 No 0 15 No 5 5 No 0
Yes 4 Yes 4 3 Yes 2 2 Yes 100 3 Yes 3 3 Yes 90 8 No 3 3 Yes 60 10 No 4 4
No No 15 Yes 5 5 No 24 15 No 5 5 No 8 atropine psychosis15 No 5 5 No 0 15 No 5 5
No No 15 Yes 5 5 No 96 15 Yes 5 5 No 84 15 No 5 5 No 8 15 No 5 5
Yes 37 Yes 35 8 Yes 3 3 Yes 110 3 Yes 3 3 Yes 240 3 Yes 3 3 Yes 104 3 Yes 3 3
Yes 4 Yes 3 13 Yes 3 3 Yes 164 10 No 4 4 Yes 48 10 No 4 4 Yes 8 15 No 5 5
Yes 9 Yes 9 9 Yes 3 3 Yes 120 3 Yes 3 3 Yes 344 3 Yes 3 3 Yes 266 3 Yes 3 3
No No 15 No 5 5 No 18 15 No 5 5 No 0 15 No 5 5 No 0
Yes 6 Yes 5 14 No 4 4 No 0 15 Yes 5 5 No 26 15 No 5 5 No 17 15 No 4 4
Yes 7 Yes 5 15 No 4 4 No 2 6 Yes 4 4 Yes 79 10 No 5 5 Yes 48 10 No 5 5
Yes 25 Yes 25 3 Yes 3 3 Yes 392 8 Yes 3 3 Yes 90 10 Yes 3 3 Yes 2 5 No 2 2
Yes 5 Yes 4 10 Yes 4 4 Yes 194 6 No 4 4 Yes 74 10 No 4 4 Yes 0 10 No 5 5
No No
Yes 10 Yes 8 3 Yes 3 3 Yes 260 3 No 3 3 Yes 44 8 No 3 3 Yes 6 10 No 4 4
No No 15 No 4 4 No 34 15 No 5 5 No 25 15 No 5 5 No 12 15 No 5 5
No Yes 1 3 Yes 3 3 Yes 48
Yes 6 Yes 5 13 Yes 3 3 Yes 558 10 No 4 4 Yes 49 10 No 4 4 Yes 12 10 No 4 4
Yes 4 Yes 2 3 Yes 3 3 Yes 254 10 No 4 4 Yes 203 15 No 5 5 No 91 15 No 5 5
Yes 10 Yes 8 2 Yes 3 3 Yes 228 7 No 3 3 Yes 45 10 No 5 5 Yes 9 10 No 5 5
No No 15 No 5 5 No 30 15 No 5 5 No 40 15 No 5 5 No 0 15 No 5 5
No No 15 No 5 5 No 96 15 No 5 5 No 8 15 No 5 5 No 20 15 No 5 5
Yes 2 No 15 No 5 5 No 140 15 No 5 5 No 22 15 No 5 5 No 8 15 Yes 5 5
No No 15 No 5 5 No 46 15 No 5 5 No 12 15 No 5 5 No 0 15 No 5 5
No No 15 No 5 5 No 0
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 d4mv  d4atrodose  d4anyoth  d5gcs  d5cc  d5ul  d5ll  d5mv  d5atrodose  d5anyoth  d6gcs  d6cc  d6ul  d6ll  d6mv  d6atrodose  d6anyoth  d7gcs  d7cc  d7ul  d7ll  d7mv  d7atrodose  d7anyoth  d8gcs  d8cc  d8ul  d8ll  d8mv 
No 0 15 No 5 5 No 0 15 No 5 5 No 0 15 No 5 5 No 0 15 No 5 5 No
No 0 15 No 5 5 No 0
Yes 0 7 No 3 3 Yes 0 7 No 3 3 Yes 0 7 No 3 3 Yes 0 10 No 4 4 Yes
Yes 0 10 No 4 4 Yes 0 10 No 5 5 Yes 0 15 Yes 5 5 No 0
No 0 15 No 5 5 No 0 15 No 5 5 No 0 15 No 5 5 No 0
No 0
No 0 15 No 5 5 No 0
No 0 15 No 5 5 No 0 15 No 5 5 No 0 15 No 5 5 No 0
No 5 15 No 5 5 No 10 15 No 5 5 No 1
Yes 20 10 No 4 4 Yes 0 15 No 5 5 No 0 15 No 5 5 No 0
No 20 15 No 5 5 No 0 15 No 5 5 No 0 15 No 5 5 No 0
No 2 15 No 5 5 No 2 15 No 5 5 No 0 15 No 5 5 No 0
No 0 15 No 5 5 No 0
Yes 0 14 No 5 5 No 0 15 No 5 5 No 0 15 No 5 5 No 0 15 No 5 5 No
Yes 34 15 No 5 5 No 0 15 No 5 5 No 0 15 No 5 5 No 0 15 No 5 5 No
No 0 15 No 5 5 No 0 15 No 5 5 No 0
No 8 15 No 5 5 No 6 15 No 5 5 Yes 0
Yes 102 3 Yes 3 3 Yes 220 3 No 3 3 Yes 0 3 No 3 3 No 0 pneumonthorax3 No 3 3 Yes
No 0 15 No 5 5 No 0 15 No 5 5 No 0
Yes 104 3 Yes 3 3 Yes 60 3 No 3 3 Yes 0 3 No 3 3 Yes 0 3 No 3 3 Yes
No 12 atropine psychosis15 No 3 3 No 1 10 No 3 3 No 0 10 No 3 3 Yes 0 10 No 3 3 Yes
Yes 8 10 No 4 4 Yes 0 10 No 5 5 No 0 15 No 5 5 No 0 15 No 5 5 No
Yes 0 5 No 2 2 Yes 0 4 No 2 2 Yes 6 10 No 2 2 Yes 23 10 No 3 3 Yes
Yes 0 15 No 5 5 No 0 15 No 5 5 No 0 15 No 5 5 No 0 15 No 5 5 No
Yes 0 10 No 4 4 Yes 0 10 No 4 4 Yes 0 10 No 4 4 Yes 0 10 No 5 5 Yes
No 2 15 No 5 5 No 0 15 No 5 5 No 0
Yes 62 10 No 5 5 Yes 56 15 No 5 5 No 5 15 No 5 5 No 0 15 No 5 5 No
No 14 15 No 5 5 No 0 15 No 5 5 No 0
Yes 12 10 No 5 5 Yes 3 15 Yes 5 5 Yes 145 10 Yes 5 5 Yes 119 10 No 5 5 Yes
No 0 15 No 5 5 No 0
No 0 15 No 5 5 No 0 15 No 5 5 No 0
No 4 14 Yes 4 4 No 6 14 Yes 4 4 No 24 15 No 5 5 No 0 15 No 5 5 No
No 0 15 No 5 5 No 0 15 No 5 5 No 0 15 No 5 5 No 0
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 d8atrodose  d8anyoth  d9gcs  d9cc  d9ul  d9ll  d9mv  d9atrodose  d9anyoth  c olcris  durocc coma  durcoma  intersynd  durims mechventi1  durmv1  aspipneu1  nosopneu  cara  oppoison  outcome  dateout  timeout  cod 
0 Yes 2 No No No No No No Deliberate self harm Alive 4/30/2015
Yes 2 No No Yes 2 No No No Deliberate self harm DAMA 5/1/2015
Yes 1 No No No No No No Deliberate self harm Alive 5/15/2015
0 15 No 5 5 No 0 Yes 2 No Yes 5 Yes 8 No Yes No Deliberate self harm Alive 6/1/2015
Yes 3 No No Yes 6 No No No Deliberate self harm Alive 6/18/2015
Yes 3 No No Yes 2 No No No Deliberate self harm Alive
No No No No No No No Deliberate self harm Alive
No No No No No No No Deliberate self harm Alive
Yes 2 No No Yes 3 No No No Deliberate self harm Alive
Yes 3 No No No No No No Deliberate self harm Alive 6/19/2016
Yes 2 No Yes 2 Yes 6 No No No Deliberate self harm Alive
Yes 1 No No No No No No Deliberate self harm Alive
No No No No No No No Deliberate self harm Alive
Yes No No Yes 0.5 No No Yes Deliberate self harm Dead 8/4/2015 5.4 cardiorespiratory arrest
Yes 1 No No No No No No Deliberate self harm Alive
0 Yes 2 No No No No No No Deliberate self harm Alive
No No No 4 No No No No Deliberate self harm DAMA
Yes 1 No No No No No No Deliberate self harm DAMA 6/14/2016
No No No No No No No Deliberate self harm Alive 7/31/2015
0 Yes 2 No No Yes 4 No No No Deliberate self harm Alive 7/7/2015
Yes 1 No No No No No No Deliberate self harm Alive
Yes 2 No No No No No No Deliberate self harm Alive
0 3 No 3 3 Yes 0 Yes 4 No Yes 10 Yes 35 Yes Yes No Deliberate self harm Alive
Yes 1 No No Yes 3 No No No Deliberate self harm Alive
0 3 No 3 3 Yes 0 Yes 5 No No Yes 9 No Yes No Deliberate self harm Dead 12/12/2015 7.05 refractory shock with severe metabolic acidosis
No No No No No No No Deliberate self harm Alive
0 10 No 3 3 Yes 0 Yes 1 No Yes 6 Yes 5 No No No Deliberate self harm Alive
0 15 No 5 5 No 0 Yes 1 No No Yes 5 No Yes No Deliberate self harm Alive
25 10 No 3 3 Yes 18 Yes 3 No Yes 25 Yes 25 Yes Yes No Deliberate self harm DAMA
0 Yes 1 No No Yes 4 No No No Deliberate self harm Alive
No No No Alive
0 15 No 5 5 No 0 Yes 1 No No Yes 8 Yes No No Deliberate self harm Alive
No No No No No No No Deliberate self harm Alive
Yes 12 No No Yes 12 No No No Deliberate self harm DAMA
0 15 No 5 5 No 0 Yes 1 No No Yes 5 No No No Deliberate self harm Alive
Yes 1 No No Yes 2 No No No Deliberate self harm Alive
0 15 No 5 5 No 0 Yes 4 No Yes 2 Yes 8 No Yes No Deliberate self harm Alive
No No No No No No No Deliberate self harm Alive
No No No No No No No Deliberate self harm Alive
0 15 No 5 5 No 0 Yes 3 No Yes 2 No No No No Deliberate self harm Alive
No No No No No No No Deliberate self harm Alive
No No No No No No No Deliberate self harm DAMA
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 duricucare  durhosp  lagtimeop  prelavage  plvomit  plie  plac  plgl  volcomp  severity  lowgcs  weakadmin  cholcrises ccdur  intersynd1  isdur  coma1  comadur  nosopneu1  actichar  nod  icucare  icudur  atropine1 
0 8 1.2 Absent 300 Mild No No Present 2 Absent Absent Absent Present 1 Absent Present
3 3 4.3 PresentYes Yes No No 60 Severe Yes Yes Present 2 Absent Absent Absent Present 1 Present 3 Present
0 5 3.3 Absent 20 Mild No No Present 1 Absent Absent Absent Present 1 Absent Absent
9 11 1 Absent 60 Severe Yes Yes Present 2 Present 5 Absent Present Present 1 Present 9 Present
6 7 3.5 PresentYes Yes No Yes 75 Severe Yes Yes Present 3 Absent Absent Absent Absent Present 6 Present
5 7 3 Absent 100 Moderate No No Present 3 Absent Absent Absent Present 1 Present 5 Present
0 5 2 Absent 20 Mild No No Absent Absent Absent Absent Present 1 Absent Present
0 5 2 Absent 50 Mild No No Absent Absent Absent Absent Absent Absent Present
1 7 1 PresentYes Yes Yes Yes 20 Severe Yes Yes Present 2 Absent Absent Absent Present 1 Present 1 Present
0 6 6 PresentNo No No Yes 100 Moderate Yes No Present 3 Absent Absent Absent Absent 0 Absent Present
6 7 6 PresentYes No No Yes 75 Severe Yes Yes Present 2 Present 2 Absent Absent Absent Present 6 Present
0 7 1.3 PresentYes No No Yes 25 Mild No No Present 1 Absent Absent Absent Present 1 Absent Present
0 7 4.3 PresentYes No No Yes 50 Mild No No Absent Absent Absent Absent Present 1 Absent Present
0 1 2.45 PresentYes No No Yes 50 Mild Yes No Present 1 Absent Absent Absent Present 1 Absent Present
0 5 1.45 PresentYes No No Yes 100 Mild No No Present 1 Absent Absent Absent Present 1 Absent Present
5 8 1.15 PresentYes No No Yes 50 Severe Yes Yes Present 2 Absent Absent Absent Present 1 Present 5 Present
0 1 4 Absent Latent No No Absent 3 Absent 4 Absent Absent Absent Absent 0 Absent
0 1 2 PresentYes No No Yes 50 Mild No No Present 1 Absent Absent Absent Present 1 Absent Present
0 3 3 Absent 10 Latent No No Absent Absent Absent Absent Present 0 Absent Absent
4 8 2.3 PresentYes No No Yes 50 Severe Yes Yes Present 2 Absent Absent Absent Present 1 Present 4 Present
0 6 1.45 PresentYes No No Yes 50 Mild No No Present 1 Absent Absent Absent Present 1 Absent Present
0 6 1.15 Absent 30 Mild No No Present 2 Absent Absent Absent Present 1 Absent Present
37 41 2.3 Absent 100 Severe Yes Yes Present 4 Present 10 Absent Present Present 1 Present 37 Present
4 6 3.3 PresentYes No No Yes Severe Yes Yes Present 1 Absent Absent Absent Present 1 Present 4 Present
9 9 2.3 PresentYes No No Yes 100 Severe Yes Yes Present 5 Absent Absent Present Present 1 Present 9 Present
0 3 1.3 PresentNo No No Yes 50 Latent No No Absent Absent Absent Absent Present 1 Absent Present
6 14 4 PresentNo Yes No No 100 Moderate Yes Yes Absent Present 6 Absent Absent Present 1 Present 6 Present
7 11 3 PresentYes No No Yes 40 Moderate No No Present 1 Absent Absent Present Present 1 Present 7 Present
25 25 4.2 Absent 100 Severe Yes Yes Present 3 Present 25 Absent Present Present 1 Present 25 Present
5 8 3 PresentYes No No Yes 100 Severe Yes Yes Present 1 Absent Absent Absent Present 1 Present 5 Present
5 Absent Absent Absent Present
10 12 4.3 PresentYes No No Yes Severe Yes Yes Present 1 Absent Absent Absent Present 1 Present 10 Present
0 6 5 PresentYes No No Yes 10 Mild No No Absent Absent Absent Absent Present 1 Absent Present
0 1 2 PresentYes No No Yes 100 Severe Yes Yes Present 1 Absent Absent Absent Present 1 Absent Present
6 11 3.45 PresentYes No No Yes Severe Yes Yes Present 1 Absent Absent Absent Present 1 Present 5 Present
4 6 1.4 PresentNo No No Yes 100 Severe Yes Yes Present 1 Absent Absent Absent Present 1 Present 4 Present
10 14 5 PresentYes No No Yes 100 Severe Yes Yes Present 4 Present 2 Absent Present Absent Present 7 Present
0 5 2.15 Absent 15 Latent No No Absent Absent Absent Absent Present 1 Absent Present
0 5 2 PresentYes No No Yes 50 Mild No No Absent Absent Absent Absent Present 1 Absent Present
2 9 3 PresentYes No No Yes 5 Mild No No Present 3 Present 2 Absent Absent Present 1 Present 2 Present
0 7 2 PresentNo No No Yes 10 Latent No No Absent Absent Absent Absent Present 1 Absent Present
0 1 3.45 Absent 100 Latent No No Absent Absent Absent Absent Absent Absent Absent
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 atropinend  totalatro  mechvent mvdur  tracheo  antibiotic  laryngos1 aspipneu2  arrhyth  esogastric  cardiac1  finalout  opcomp  baglaspi  baopcon  baamountop  bbglaspi  bbopcon  bbamountop  bcglaspi 
2 60 Absent Absent Absent No No Absent Absent Absent Discharge 275 550 350
2 14 Present 2 Absent Present No No Absent Absent Absent DAMA 100 200 230
Absent Absent Absent No No Absent Absent Absent Discharge 0 300 310
3 376 Present 8 Absent Present No No Absent Absent Absent Discharge 250 125 140
3 114 Present 6 Absent Present No No Absent Absent Absent Discharge 30 180 175
3 225 Present 2 Absent Present No No Absent Absent Absent Discharge 50 150 100
1 1 Absent Absent Absent No No Absent Absent Absent Discharge 0 350 200
2 24 Absent Absent Absent No No Absent Absent Absent Discharge 100 220 230
2 51 Present 3 Absent Present No No Absent Absent Absent Discharge 10 110 215
6 70 Absent Absent Present No No Absent Absent Absent Discharge 5 250 220
4 592 Present 6 Absent Present No No Absent Absent Absent Discharge 180 70 120
4 207 Absent Absent Absent No No Absent Absent Absent Discharge 10 75 275
4 8 Absent Absent Absent No No Absent Absent Absent Discharge 0 150 180
1 34 Present 1 Absent Absent No No Absent Absent Present Death 0 180 200
2 21 Absent Absent Absent No No Absent Absent Absent Discharge 10 240 225
2 58 Present 4 Absent Present No No Absent Absent Absent Discharge 600 150 120
Absent Absent Absent No No Absent Absent Absent Discharge 0 300 210
1 4 Absent Absent Absent No No Absent Absent Absent Discharge 33 270 70
0 Absent Absent Absent No No Absent Absent Absent Discharge 15 100 110
4 284 Present 4 Absent Present No No Absent Absent Absent Discharge 350 225 250
2 32 Absent Absent Absent No No Absent Absent Absent Discharge 30 130 220
5 202 Absent Absent Absent No No Absent Absent Absent Discharge 100 170 220
5 776 Present 35 Present Present No Yes Absent Absent Absent Discharge 10 140 170
3 220 Present 3 Absent Present No No Absent Absent Absent Discharge 0 200 200
5 894 Present 9 Absent Present No No Absent Absent Absent Death 50 210 200
1 18 Absent Absent Absent No No Absent Absent Absent Discharge 0 170 100
4 56 Present 5 Absent Present No No Absent Absent Absent Discharge 0 200 250
4 137 Present 5 Absent Present No No Absent Absent Absent Discharge 100 120 200
9 556 Present 25 Present Present No Yes Absent Absent Absent DAMA 150 160 220
2 268 Present 4 Absent Present No No Absent Absent Absent Discharge 20 190 180
1 72 Absent Absent Absent No No Absent Absent Absent Discharge 0 200 300
3 310 Present 8 Absent Present No Yes Absent Absent Absent Discharge 20 100 220
4 73 Absent Absent Present No No Absent Absent Absent Discharge 0 200 500
1 48 Present 1 Absent Absent No No Absent Absent Absent DAMA 10 200 210
6 742 Present 5 Absent Present No No Absent Absent Absent Discharge 0 170 190
4 562 Present 2 Absent Present No No Absent Absent Absent Discharge 100 290 400
10 764 Present 8 Absent Present No No Absent Absent Absent Discharge 0 100 160
2 70 Absent Absent Absent No No Absent Absent Absent Discharge 0 180 240
3 124 Absent Absent Absent No No Absent Absent Absent Discharge 0 240 260
6 204 Absent Absent Absent No No Absent Absent Absent Discharge 90 200 210
2 58 Absent Absent Absent No No Absent Absent Absent Discharge 20 25 25
Absent Absent Absent No No Absent Absent Absent Discharge 0 180 190
 
 
135 
 
 
 bcopcon  bcamountop  bdglaspi OP compound A P1 B P2 C P3 D P4 Total 
750 Triazophos 101 74.81481481 4.9 3.62962963 24.4 18.07407407 4.7 3.481481481 135
300 methlyparathion 50.3 67.60752688 20.1 27.01612903 4 5.376344086 0 0 74.4
395 no std
235 not identified 0 0 0 0 0
215 not identified 0 0 0 0 0
110 methlyparathion 20482 99.72102262 35.9 0.174786872 21.4 0.104190503 0 0 20539.3
400 Triazophos 0 18073 88.66311157 2285 11.20982736 25.9 0.127061063 20383.9
275 Prophenophos 241 100 0 0 0 0 0 0 241
260 not identified 0 0 0 0 0
190 not identified 0 0 0 0 0
210 not identified 0 0 0 0 0
75 not identified 0 0 0 0 0
250 no std 0 0 0
200 not identified 0 0 0 0
230 not identified 0 0 0 0 0
250 chlorpyriphos + triazophos2173 98.51747744 30 1.360112436 0 0 2.7 0.122410119 2205.7
150 Triazophos 0 12.6 49.80237154 12.7 50.19762846 0 0 25.3
165 Prophenophos 22 51.1627907 21 48.8372093 0 0 0 0 43
140 not identified 0 0 0 0 0
170 chlorpyriphos 3581 100 0 0 0 0 0 0 3581
200 chlorpyriphos 0 0 0 0 0
220 Prophenophos 47.3 60.56338028 21 26.88860435 0 0 9.8 12.54801536 78.1
220 Triazophos 20482 81.96406419 2674 10.70070831 1307 5.230301333 526 2.104926168 24989
210 chlorpyriphos 0 6.3 44.68085106 4.3 30.4964539 3.5 24.82269504 14.1
Triazophos 650 77.10557533 119 14.11625148 74 8.778173191 0 0 843
320 not identified 0 0 0 0
360 chlorpyriphos 0 83.6 84.44444444 8.7 8.787878788 6.7 6.767676768 99
340 chlorpyriphos 114 86.56036446 9.8 7.441154138 7.9 5.998481397 0 0 131.7
190 no std 0
220 methlyparathion 51.8 38.45582777 1.9 1.410541945 50.6 37.56495917 30.4 22.56867112 134.7
200 no std
310 no std 0
190 no std
220 chlorpyriphos 354 100 0 0 0 0 0 0 354
250 no std
210 unknown 9228 95.36013227 409 4.226516482 0 0 40 0.413351245 9677
200 malathion 0 13.7 18.94882434 38.3 52.97372061 20.3 28.07745505 72.3
120 chlorpyriphos 0 11.2 39.85765125 10.5 37.36654804 6.4 22.77580071 28.1
210 quinalphos 0 257 77.47965029 45.1 13.59662345 29.6 8.923726259 331.7
250 chlorpyriphos 85.7 85.44366899 14.6 14.55633101 0 0 0 0 100.3
100 chlorpyriphos 10.8 52.94117647 4.7 23.03921569 4.9 24.01960784 0 0 20.4
160 no std
